



STN Structure : query.str



chain nodes :
 10 19 20 21 22 23 27 28 30 31 32 33 37 38 39
 ring nodes :
 1 2 3 4 5 6 7 8 9 11 12 13 14 15 16
 chain bonds :
 1-39 2-30 3-38 4-37 8-31 10-13 10-31 11-33 14-27 15-28 16-19 20-22 21-23
 31-32
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 11-12 11-16 12-13 13-14 14-15
 15-16
 exact/norm bonds :
 2-30 5-7 6-9 7-8 8-9 8-31 14-27 15-28 16-19 20-22 21-23 31-32
 exact bonds :
 1-39 3-38 4-37 10-13 10-31 11-33
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16
 isolated ring systems :
 containing 1 : 11 :


G2:H,Ak

G3:Ak,H,[*1],[*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS 11:Atom
 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 19:CLASS 20:CLASS 21:CLASS 22:CLASS
 23:CLASS 27:CLASS 28:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 37:CLASS 38:CLASS
 39:CLASS

STN Structure : query.str



chain nodes :

10 19 20 21 22 23 27 28 30 32 33 45 46 47 56 57 58 59 60

ring nodes :

1 2 3 4 5 6 7 8 9 11 12 13 14 15 16 36 37 38 39 40 41 42 43 44 48
49 50 51 52 53

chain bonds :

8-32 10-13 10-32 11-33 14-27 15-28 16-19 20-22 21-23 43-45 45-46 45-47 47-50
48-56 51-57 52-58 53-59

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 11-12 11-16 12-13 13-14 14-15
15-16 36-37 36-41 37-38 38-39 39-40 40-41 40-42 41-44 42-43 43-44 48-49 48-53
49-50 50-51 51-52 52-53

exact/norm bonds :

5-7 6-9 7-8 8-9 8-32 14-27 15-28 16-19 20-22 21-23 40-42 42-43 43-45 45-46
51-57 52-58 53-59

exact bonds :

10-13 10-32 11-33 41-44 43-44 45-47 47-50 48-56

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16 36-37 36-41
37-38 38-39 39-40 40-41 48-49 48-53 49-50 50-51 51-52 52-53

isolated ring systems :

containing 1 : 11 : 36 : 48 :

G2:H,Ak

G3:Ak,H,[*1],[*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 19:CLASS 20:CLASS 21:CLASS 22:CLASS
23:CLASS 27:CLASS 28:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 36:Atom 37:Atom
38:Atom 39:Atom 40:Atom 41:Atom 42:Atom 43:Atom 44:Atom 45:CLASS 46:CLASS
47:CLASS 48:Atom 49:Atom 50:Atom 51:Atom 52:Atom 53:Atom 56:CLASS 57:CLASS
58:CLASS

59:CLASS 60:CLASS 61:CLASS

fragments assigned product role:


containing 36

fragments assigned reactant/reagent role:

containing 1


Session text above this point is available in the transcript,
available from the **Transcript Assistant** on the toolbar.

pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 115046-04-3 HCAPLUS

CN 1H-Benzimidazole, 5-(cyclopropylmethoxy)-2-[[4-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 115046-05-4 HCAPLUS

CN 1H-Benzimidazole, 4-(cyclopropylmethoxy)-2-[[3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 115046-06-5 HCAPLUS

CN 1H-Benzimidazole, 5-(cyclopropylmethoxy)-2-[[3,4,5-trimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 115046-07-6 HCAPLUS

CN 1H-Benzimidazole, 4-(cyclopropylmethoxy)-2-[[3,4,5-trimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 115046-08-7 HCAPLUS

CN 1H-Benzimidazole, 4-(cyclopropylmethoxy)-2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 115046-09-8 HCAPLUS

CN 1H-Benzimidazole, 5-(cyclopropylmethoxy)-2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 115046-10-1 HCAPLUS

CN 1H-Benzimidazole, 5-(cyclopropylmethoxy)-2-[[4-methoxy-5-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 115046-11-2 HCAPLUS

CN 1H-Benzimidazole, 4-(cyclopropylmethoxy)-2-[[4-methoxy-5-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




L11 ANSWER 47 OF 69 HCAPLUS COPYRIGHT 2002 ACS

Full Text Citing References

ACCESSION NUMBER: 1988:131819 HCAPLUS
DOCUMENT NUMBER: 108:131819
TITLE: Process for the preparation of the gastric secretion inhibitor 5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]benzimidazole
PATENT ASSIGNEE(S): Laboratorios Hubber S. A., Spain
SOURCE: Span., 8 pp.
CODEN: SPXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Spanish
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>ES 550070</u>	A1	19870316	<u>ES 1985-550070</u>	19851218

GI




AB The title compd. I ($n = 1$) (II; i.e. omeprazole), an inhibitor of gastric secretion, is prepd. from methoxyphenylenediamine III and [(dimethylmethoxypyridyl)methylthio]formic acid IV. A mixt. of III and IV in 4N HCl was refluxed for 40 min to give I ($n = 0$) (V), isolated as V.HCl. An aq. mixt. of V.HCl and NaIO₄ was stirred at -5 to -10° for 1 h to give 75% II after workup and recrystn.

IT 73590-85-9P 108928-02-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and oxidn. of)

RN 73590-85-9 HCAPLUS

CN 1H-Benzimidazole, 5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]- (9CI) (CA INDEX NAME)




RN 108928-02-5 HCAPLUS
CN 1H-Benzimidazole, 5-methoxy-2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-, hydrochloride (9CI) (CA INDEX NAME)



x HCl

IT 73590-58-6P, Omeprazole
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, from methoxyphenylenediamine and
[(dimethylmethoxypyridyl)methylthio]formic acid)

RN 73590-58-6 HCAPLUS
CN 1H-Benzimidazole, 5-methoxy-2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



L11 ANSWER 48 OF 69 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1988:6051 HCAPLUS

DOCUMENT NUMBER: 108:6051

TITLE: Preparation of pyridothiadiazinobenzimidazoles as ulcer inhibitors

INVENTOR(S): Nohara, Akira; Maki, Yoshitaka

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: Eur. Pat. Appl., 20 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 233760	A1	19870826	EP 1987-301243	19870213
EP 233760	B1	19910515		
R: BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
CA 1276017	A1	19901106	CA 1987-529446	19870211
JP 62277392	A2	19871202	JP 1987-29998	19870212
JP 07098825	B4	19951025		
US 4769456	A	19880906	US 1987-14352	19870213

PRIORITY APPLN. INFO.: JP 1986-29569 19860213

OTHER SOURCE(S): CASREACT 108:6051

GI




AB The title compds. (I; R1 = H, MeO, CF₃; R2,R3 = H, Me; R4 = fluoroalkyl; X = pharmaceutically acceptable anion) were prepd. as ulcer inhibitors (no data). 2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methylsulfanyl]benzimidazole and HBF₄ in MeOH were heated at 37.degree. to give I(R1 = R3 = H, R4 = CH₂CF₃) (II).BF₄⁻.

IT 103577-38-4P 103577-39-5P 103577-40-8P
103577-41-9P 103577-42-0P 103577-80-6P
103577-81-7P 103577-82-8P 103577-83-9P
103577-84-0P 103577-85-1P 103577-86-2P
103577-87-3P 103602-42-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and S-oxidn. of)


RN 103577-38-4 HCAPLUS

CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,3,3,3-pentafluoropropoxy)-2-pyridinyl]methyl]thio]- (9CI) (CA INDEX NAME)




RN 103577-39-5 HCAPLUS

CN 1H-Benzimidazole, 2-[[[4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]thio]- (9CI) (CA INDEX NAME)




RN 103577-40-8 HCAPLUS

CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]thio]- (9CI) (CA INDEX NAME)




RN 103577-41-9 HCAPLUS

CN 1H-Benzimidazole, 2-[[[5-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]thio]- (9CI) (CA INDEX NAME)




RN 103577-42-0 HCAPLUS

CN 1H-Benzimidazole, 2-[[[4-(2,2,3,3,3-pentafluoropropoxy)-2-methylpyridinyl]methyl]thio]- (9CI) (CA INDEX NAME)




RN 103577-80-6 HCAPLUS

CN 1H-Benzimidazole, 2-[[[5-methyl-4-(2,2,3,3,3-pentafluoropropoxy)-2-pyridinyl]methyl]thio]- (9CI) (CA INDEX NAME)



RN 103577-81-7 HCAPLUS

CN 1H-Benzimidazole, 2-[[[4-(2,2,3,3,3-tetrafluoropropoxy)-2-methylpyridinyl]methyl]thio]- (9CI) (CA INDEX NAME)




□N

H


RN 103577-82-8 HCAPLUS

CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,3,3,3-tetrafluoropropoxy)-2-pyridinyl]methyl]thio]- (9CI) (CA INDEX NAME)




RN 103577-83-9 HCAPLUS

CN 1H-Benzimidazole, 2-[[[5-methyl-4-(2,2,3,3,3-tetrafluoropropoxy)-2-pyridinyl]methyl]thio]- (9CI) (CA INDEX NAME)




RN 103577-84-0 HCAPLUS

CN 1H-Benzimidazole, 2-[[[3,5-dimethyl-4-(2,2,3,3,3-pentafluoropropoxy)-2-pyridinyl]methyl]thio]- (9CI) (CA INDEX NAME)




RN 103577-85-1 HCAPLUS

CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]thio]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 103577-86-2 HCAPLUS

CN 1H-Benzimidazole, 5-methoxy-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]thio]- (9CI) (CA INDEX NAME)




RN 103577-87-3 HCAPLUS

CN 1H-Benzimidazole, 5-methoxy-2-[[[4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]thio]- (9CI) (CA INDEX NAME)



RN 103602-42-2 HCAPLUS

CN 1H-Benzimidazole, 2-[[[3,5-dimethyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]thio]- (9CI) (CA INDEX NAME)




IT 103577-43-1P 103577-45-3P 103577-51-1P
103577-54-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)

(prepn. and cyclization of, pyridothiadiazinobenzimidazole by)


RN 103577-43-1 HCAPLUS

CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,3,3,3-pentafluoropropoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 103577-45-3 HCAPLUS

CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 103577-51-1 HCAPLUS

CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,3,3-tetrafluoropropoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 103577-54-4 HCAPLUS

CN 1H-Benzimidazole, 5-methoxy-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




IT 103577-44-2P 103577-46-4P 103577-47-5P
103577-48-6P 103577-49-7P 103577-50-0P
103577-52-2P 103577-53-3P 103577-55-5P
103602-43-3P

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of, as intermediate for ulcer inhibitor)


RN 103577-44-2 HCAPLUS

CN 1H-Benzimidazole, 2-[[[4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 103577-46-4 HCAPLUS

CN 1H-Benzimidazole, 2-[[[5-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 103577-47-5 HCAPLUS

CN 1H-Benzimidazole, 2-[[[3,5-dimethyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 103577-48-6 HCAPLUS

CN 1H-Benzimidazole, 2-[[[4-(2,2,3,3,3-pentafluoropropoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 103577-49-7 HCAPLUS


CN 1H-Benzimidazole, 2-[[[5-methyl-4-(2,2,3,3,3-pentafluoropropoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 103577-50-0 HCAPLUS


CN 1H-Benzimidazole, 2-[[[4-(2,2,3,3-tetrafluoropropoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)

pyridinyl)methyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 103577-52-2 HCAPLUS

CN 1H-Benzimidazole, 2-[[[5-methyl-4-(2,2,3,3-tetrafluoropropoxy)-2-pyridinyl)methyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 103577-53-3 HCAPLUS

CN 1H-Benzimidazole, 2-[[[3,5-dimethyl-4-(2,2,3,3,3-pentafluoropropoxy)-2-pyridinyl)methyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 103577-55-5 HCAPLUS

CN 1H-Benzimidazole, 5-methoxy-2-[[[4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl]- (9CI) (CA INDEX NAME)



RN 103602-43-3 HCAPLUS

CN 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




L11 ANSWER 49 OF 69 HCAPLUS COPYRIGHT 2002 ACS


Full Text Citing References

ACCESSION NUMBER: 1987:575947 HCAPLUS

DOCUMENT NUMBER: 107:175947
 TITLE: Reaction of 2-(alkylsulfinyl)-, 2-(arylsulfinyl)-, and 2-(aralkylsulfinyl)benzimidazoles with thiols: a convenient synthesis of unsymmetrical disulfides
 AUTHOR(S): Graber, David R.; Morge, Raymond A.; Sih, John C.
 CORPORATE SOURCE: Upjohn Co., Kalamazoo, MI, 49001, USA
 SOURCE: J. Org. Chem. (1987), 52(20), 4620-2
 CODEN: JOCEAH; ISSN: 0022-3263
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 107:175947
 GI



I



II


AB Unsym. disulfides were prep'd. under neutral conditions in 52-90% yield by reacting 2-sulfinylbenzimidazoles with thiols. Thus, benzylsulfinylbenzimidazole I was treated with HSCH2CO2Et in EtOH to give 75% PhCH2SSCH2CO2Et. The chief by product of the reaction is the thio ether, e.g., II, of benzimidazole and the reacting thiol.

IT 23593-22-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and oxidn. of)

RN 23593-22-8 HCAPLUS

CN 1H-Benzimidazole, 2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




IT 57237-97-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and reaction of, with benzyl and ethylthiol)

RN 57237-97-5 HCAPLUS

CN 1H-Benzimidazole, 2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)



L11 ANSWER 50 OF 69 HCAPLUS COPYRIGHT 2002 ACS

Full Text Citing
 Text References

ACCESSION NUMBER: 1987:571309 HCAPLUS
 DOCUMENT NUMBER: 107:171309
 TITLE: (H⁺-K⁺)-ATPase inhibiting 2-[(2-pyridylmethyl)sulfinyl]benzimidazoles. 1. Their reaction with thiols under acidic conditions. Disulfide containing 2-pyridinylbenzimidazoles as mimics for the inhibited enzyme
 AUTHOR(S): Sturm, Ernst; Krueger, Uwe; Senn-Bilfinger, Joerg;

CORPORATE SOURCE: Figala, Volker; Klemm, Kurt; Kohl, Bernhard; Rainer, Georg; Schaefer, Hartmann; Blake, Timothy J.; et al. Byk Gulden Lomberg Chem. Fabr. G.m.b.H., Konstanz, D-7750, Fed. Rep. Ger.


SOURCE: J. Org. Chem. (1987), 52(20), 4573-81
CODEN: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 107:171309

GI




AB A model for studying the mechanism of (H⁺-K⁺)-ATPase inhibition by the sulfoxides, I, namely, the reaction of I with thiols at low pH, was described. I were rearranged in acidic media and incorporated by the thiol to give the 2-pyridinio derivs., II. II could be isolated as the neutral ylides, III. The structure of III was unambiguously supported by detailed spectral data and by an x-ray anal. of III (R = SSCH₂CH₂OH; R₁ = 5-CF₃; R₂ = H; R₃ = Me; R₄ = OMe). The cleavage of the disulfide bond of III by thiols led to a 2nd rearrangement, generating the sulfides, IV, which contained the original mol. backbone. The reductive desulfuration of III (R = SSCH₂CH₂OH; R₁ = 5-CF₃; R₂ = R₃ = H; R₄ = OMe) resulted in degrdn. of the disulfide side-chain giving a 2-(2-methylpyridinio)benzimidazolidine, III (R = R₂ = R₃ = H; R₁ = 5-CF₃; R₄ = OMe). The O-demethylation of the 4-methoxypyridinio deriv., II (R = CH₂CH₂OH; R₁ = 6-CF₃; R₂ = R₃ = Me; R₄ = OMe; R₅ = H), was converted to the pyridone, V. The structural prerequisites essential for the reactivity of I were discussed. I are also ulcer inhibitors.

IT **110374-32-8P**

RL: SPN (Synthetic preparation); **PREP (Preparation)**
(prepn. and conversion to pyridiniobenzimidazolidine)

RN 110374-32-8 HCAPLUS

CN 1H-Benzimidazole, 2-[[[4-methoxy-2-pyridinyl)methyl]sulfonyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




IT 110374-19-1

RL: RCT (Reactant)

(reaction of, with thiols at low pH, stomach ATPase in relation to)

RN 110374-19-1 HCAPLUS

CN 1H-Benzimidazole-2-13C, 5-methoxy-2-[[4-methoxy-2-pyridinyl-1-15N)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



IT 57237-97-5 86604-66-2 86604-68-4


110374-16-8

RL: RCT (Reactant)

(reaction of, with thiols at low pH, stomach ATPase inhibition in relation to)


RN 57237-97-5 HCAPLUS

CN 1H-Benzimidazole, 2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 86604-66-2 HCAPLUS

CN 1H-Benzimidazole, 2-[[4-methoxy-2-pyridinyl)methyl]sulfinyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 86604-68-4 HCAPLUS

CN 1H-Benzimidazole, 2-[[4-methoxy-3-methyl-2-pyridinyl)methyl]sulfinyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 110374-16-8 HCAPLUS

CN 1H-Benzimidazole, 2-[[3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-5-methoxy- (9CI) (CA INDEX NAME)




L11 ANSWER 51 OF 69 HCAPLUS COPYRIGHT 2002 ACS

Full Text Citing References

ACCESSION NUMBER: 1987:439827 HCAPLUS
DOCUMENT NUMBER: 107:39827
TITLE: 2-[(2-Pyridylmethyl)sulfinyl]benzimidazole derivatives as ulcer inhibitors
INVENTOR(S): Uchida, Minoru; Morita, Seiji; Chihiro, Masatoshi
PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>JP 62061978</u>	A2	19870318	<u>JP 1985-202994</u>	19850912

GI



I


AB The title compds. (I; R1, R3 = alkyl; R2 = alkoxy), useful as ulcer inhibitors, were prepd. A soln. of [(5-fluoro-1H-benzimidazol-2-yl)sulfinyl]methylithium and 2-chloro-3,5-dimethyl-4-methoxypyridine in benzene was refluxed for 2 h to give I (R1 = R3 = Me, R2 = OMe). When administered o.p., this inhibited aspirin-induced stomach ulcer in rats with an ED50 of 0.35 mg/kg. Tablets contg. I and pharmaceutical carriers are prepd.

IT 108662-48-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and oxidn. of)

RN 108662-48-2 HCAPLUS

CN 1H-Benzimidazole, 5-fluoro-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]- (9CI) (CA INDEX NAME)




IT 108662-50-6P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); **PREP**
(Preparation); USES (Uses)
 (prepn. of, as ulcer inhibitor)

RN 108662-50-6 HCAPLUS

CN 1H-Benzimidazole, 5-fluoro-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




L11 ANSWER 52 OF 69 HCAPLUS COPYRIGHT 2002 ACS

Full Citing
Text References

ACCESSION NUMBER: 1987:439811 HCAPLUS
 DOCUMENT NUMBER: 107:39811
 TITLE: Process for the preparation of omeprazole
 INVENTOR(S): Garcia Bernardo, Julio
 PATENT ASSIGNEE(S): Tamarang S. A., Spain; Laboratorios Boizot S. A.
 SOURCE: Span., 9 pp.
 CODEN: SPXXAD
 DOCUMENT TYPE: Patent
 LANGUAGE: Spanish
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>ES 540147</u>	A1	19860216	<u>ES 1985-540147</u>	19850205

GI




AB The antiulcer agent omeprazole (I; n = 1) (II) is prepd. as follows.
 3-MeC6H4IO was added to a soln. of [(pyridylmethyl)thio]benzimidazole
 deriv. I (n = 0) in aq. EtCO2H and the mixt. was stirred at room temp. for
 20 h to give 90% II.

IT 73590-85-9

RL: RCT (Reactant)
 (oxidn. of, by methyl iodide)

RN 73590-85-9 HCAPLUS

CN 1H-Benzimidazole, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]- (9CI) (CA INDEX NAME)




IT 73590-58-6P, Omeprazole

RL: SPN (Synthetic preparation); **PREP (Preparation)**
(prepn. of, by **oxidn.** of [(pyridylmethyl)thio]benzimidazole
deriv. with methylidosobenzene)

RN 73590-58-6 HCAPLUS

CN 1H-Benzimidazole, 5-methoxy-2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




L11 ANSWER 53 OF 69 HCAPLUS COPYRIGHT 2002 ACS

Full Citing
Text References

ACCESSION NUMBER: 1987:439810 HCAPLUS
DOCUMENT NUMBER: 107:39810
TITLE: Process for the preparation of 2-[2-(3,5-dimethyl-4-methoxypyridyl)methylsulfinyl]-5-methoxybenzimidazole
INVENTOR(S): Rubio Zurita, Pelayo; Rubio Zurita, Salvador
PATENT ASSIGNEE(S): Laboratorios Rubio S. A., Spain
SOURCE: Span., 11 pp.
CODEN: SPXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Spanish
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>ES 543816</u>	<u>A1</u>	<u>19860116</u>	<u>ES 1985-543816</u>	<u>19850601</u>

GI




AB The title compd. I (n = 1) (II; i.e. the antiulcer agent omeprazole) is prepd. as follows. An aq. soln. of I-HCl (n = 0) was treated with powd. m-ClC6H4C(O)OOH at 0° to give II.

IT 108928-02-5P

RL: **RCT (Reactant)**; SPN (Synthetic preparation); PREP
(Preparation)
(prepn. and **oxidn.** of)

RN 108928-02-5 HCAPLUS

CN 1H-Benzimidazole, 5-methoxy-2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-, hydrochloride (9CI) (CA INDEX NAME)




x HCl

IT **73590-58-6P**, Omeprazole

RL: SPN (Synthetic preparation); **PREP (Preparation)**
(prepn. of, by **oxidn.** of [(pyridylmethyl)thio]benzimidazole deriv.)

RN **73590-58-6** HCAPLUS


CN **1H-Benzimidazole, 5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-** (9CI) (CA INDEX NAME)



L11 ANSWER 54 OF 69 HCAPLUS COPYRIGHT 2002 ACS


Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER: 1987:84476 HCAPLUS
DOCUMENT NUMBER: 106:84476
TITLE: The preparation of carbon-14-, sulfur-35-, and carbon-13-labeled forms of omeprazole
AUTHOR(S): Crowe, A. M.; Ife, R. J.; Mitchell, M. B.; Saunders, D.
CORPORATE SOURCE: Smith Kline and French Res. Ltd., The Frythe/Welwyn/Hertfordshire, AL6 9AR, UK
SOURCE: J. Labelled Compd. Radiopharm. (1986), 23(1), 21-33
CODEN: JLCRD4; ISSN: 0362-4803
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 106:84476
AB Omeprazoles labeled with carbon-13 or -14 at the benzimidazole position, sulfur-35, or carbon-14 at the methylene position (4 compds.) were prepd.
IT **106658-16-6P 106658-19-9P 106658-27-9P**
RL: **RCT (Reactant)**; SPN (Synthetic preparation); **PREP** (Preparation)
(prepn. and **oxidn.** of)
RN **106658-16-6** HCAPLUS
CN **1H-Benzimidazole-2-14C, 5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-** (9CI) (CA INDEX NAME)




RN **106658-19-9** HCAPLUS

CN **1H-Benzimidazole, 5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-35S]-** (9CI) (CA INDEX NAME)




RN 106658-27-9 HCAPLUS
CN 1H-Benzimidazole, 5-methoxy-2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl-14C]thio]- (9CI) (CA INDEX NAME)




IT 106658-17-7P 106658-20-2P 106658-22-4P
106658-28-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)


RN 106658-17-7 HCAPLUS
CN 1H-Benzimidazole-2-14C, 5-methoxy-2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 106658-20-2 HCAPLUS
CN 1H-Benzimidazole, 5-methoxy-2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 106658-22-4 HCAPLUS
CN 1H-Benzimidazole-2-13C, 5-methoxy-2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 106658-28-0 HCAPLUS
CN 1H-Benzimidazole, 5-methoxy-2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl-14C]sulfinyl]- (9CI) (CA INDEX NAME)




L11 ANSWER 55 OF 69 HCAPLUS COPYRIGHT 2002 ACS

Full Text Citing
References

ACCESSION NUMBER: 1987:50208 HCAPLUS
DOCUMENT NUMBER: 106:50208
TITLE: Omeprazole
INVENTOR(S): Linan Castellet, Isidro; Oliver Mir, Monica
PATENT ASSIGNEE(S): Farmhispania, S. A., Spain; Bioiberica S. A.
SOURCE: Span., 9 pp.
CODEN: SPXXAD
DOCUMENT TYPE: Patent
LANGUAGE: Spanish
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>ES 539793</u>	A1	19851201	<u>ES 1985-539793</u>	19850123

GI




AB Sulfide I (n = 0) was converted to Omeprazole, I (n = 1), useful as a gastric secretion inhibitor (no data). I (n = 0) was **oxidized** by PhIO in HOAc (catalyst) to give Omeprazole. Also used as catalyst was (CCl3CO)2O.

IT 73590-58-6P, Omeprazole

RL: SPN (Synthetic preparation); **PREP (Preparation)**
(prepn. of, as gastric secretion inhibitor)

RN 73590-58-6 HCAPLUS

CN 1H-Benzimidazole, 5-methoxy-2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




IT 73590-85-9

RL: **RCT (Reactant)**

(S-oxidn. of, by iodosobenzene, catalysts for)

RN 73590-85-9 HCAPLUS

CN 1H-Benzimidazole, 5-methoxy-2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]- (9CI) (CA INDEX NAME)



L11 ANSWER 56 OF 69 HCAPLUS COPYRIGHT 2002 ACS


Full Text Citing
References

ACCESSION NUMBER: 1986:553060 HCAPLUS
DOCUMENT NUMBER: 105:153060
TITLE: Benzimidazolyl benzyl sulfoxides and benzoxazole and benzothiazole analogs
INVENTOR(S): Cox, David; Ingall, Anthony Howard; Suschitzky, John Louis
PATENT ASSIGNEE(S): Fisons PLC, UK
SOURCE: Fr. Demande, 51 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>FR 2567123</u>	A1	19860110	<u>FR 1985-10337</u>	19850705
FR 2567123	B1	19910531		
<u>ZA 8505030</u>	A	19860528	<u>ZA 1985-5030</u>	19850603
<u>GB 2161160</u>	A1	19860108	<u>GB 1985-16434</u>	19850628
GB 2161160	B2	19890524		
<u>EP 174717</u>	A1	19860319	<u>EP 1985-304626</u>	19850628
EP 174717	B1	19920122		
R: AT, DE, NL, SE				
<u>AT 71942</u>	E	19920215	<u>AT 1985-304626</u>	19850628
<u>AU 8544441</u>	A1	19860109	<u>AU 1985-44441</u>	19850701
AU 580607	B2	19890119		
<u>IL 75687</u>	A1	19900319	<u>IL 1985-75687</u>	19850701
<u>DK 8503018</u>	A	19860107	<u>DK 1985-3018</u>	19850702
DK 174021	B1	20020422		
<u>CN 85106252</u>	A	19860610	<u>CN 1985-106252</u>	19850702
CN 1004756	B	19890712		
<u>FI 8502622</u>	A	19860107	<u>FI 1985-2622</u>	19850703
FI 89046	B	19930430		
FI 89046	C	19930810		
<u>BE 902818</u>	A1	19860106	<u>BE 1985-215301</u>	19850704
<u>CH 666265</u>	A	19880715	<u>CH 1985-2873</u>	19850704
<u>NO 8502729</u>	A	19860107	<u>NO 1985-2729</u>	19850705
NO 168355	B	19911104		
NO 168355	C	19920212		
<u>JP 61056168</u>	A2	19860320	<u>JP 1985-146903</u>	19850705
JP 2564509	B2	19961218		
<u>ES 544897</u>	A1	19861201	<u>ES 1985-544897</u>	19850705
<u>HU 39730</u>	A2	19861029	<u>HU 1985-4489</u>	19851125
HU 198695	B	19891128		
<u>DD 242614</u>	A5	19870204	<u>DD 1985-283389</u>	19851128
<u>SU 1524807</u>	A3	19891123	<u>SU 1985-3979903</u>	19851128
<u>BR 8506098</u>	A	19870630	<u>BR 1985-6098</u>	19851205
PRIORITY APPLN. INFO.:			<u>GB 1984-17271</u>	A 19840706
			<u>GB 1984-17272</u>	A 19840706
			<u>GB 1984-19738</u>	A 19840802
			<u>GB 1984-24346</u>	A 19840926

GB 1984-24347	A	19840926
GB 1984-24350	A	19840926
GB 1984-24351	A	19840926
GB 1984-30163	A	19841129
GB 1985-9406	A	19850412
EP 1985-304626	A	19850628

OTHER SOURCE(S): CASREACT 105:153060
GI




AB Title compds. I (X = O, S, NH, acylimino, etc.; R1-R4 = H, halo, alkoxy, alkyl, fluoroalkyl, alkanoyl, NO2, etc.; R5 = N-, O-, or S-contg. nucleophilic group) were prepd. as gastric secretion inhibitors (no data). 2-Mercaptobenzothiazole was S-alkylated by 2-Me2NC6H4CH2Cl.HCl, and the sulfide product was **oxidized** to give I (X = NH, R1-R4, = H, R5 = 2-Me2NC6H4CH2).

IT **104524-71-2P**

RL: **RCT (Reactant)**; SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction of)

RN **104524-71-2** HCAPLUS

CN **1H-Benzimidazole, 2-[[[(1-oxido-2-pyridinyl)methyl]thio]-** (9CI) (CA INDEX NAME)




IT **104524-72-3P**

RL: SPN (Synthetic preparation); **PREP (Preparation)**
(prepn. of, as gastric secretion inhibitor)

RN **104524-72-3** HCAPLUS

CN **1H-Benzimidazole, 2-[[[(1-oxido-2-pyridinyl)methyl]sulfinyl]-** (9CI) (CA INDEX NAME)




L11 ANSWER 57 OF 69 HCAPLUS COPYRIGHT 2002 ACS

Full Text Citing References

ACCESSION NUMBER: 1986:207269 HCAPLUS
DOCUMENT NUMBER: 104:207269
TITLE: Benzimidazole derivatives and their pharmaceutical use
INVENTOR(S): King, Francis David; Burrell, Gordon; Baker, Karen
PATENT ASSIGNEE(S): Beecham Group PLC, UK
SOURCE: Eur. Pat. Appl., 75 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>EP 167943</u>	<u>A2</u>	<u>19860115</u>	<u>EP 1985-108034</u>	<u>19850628</u>
R: BE, CH, DE, FR, GB, IT, LI, NL				
<u>JP 61024589</u>	<u>A2</u>	<u>19860203</u>	<u>JP 1985-147631</u>	<u>19850704</u>
PRIORITY APPLN. INFO.: GI			<u>GB 1984-17171</u>	<u>19840705</u>




AB The title compds. [I: R1 = H, alkylsulfonyl, (aryl)alkanoyl, aralkyl, alkyl, (un)substituted arylsulfonyl; R2 = H, alkyl; R3 = substituted pyridyl; R2R3 = atoms required to form a pyridine-fused carbocycle; n = 0-2], optionally substituted in the carbocyclic portion, were prepd. as antiulcer agents. Thus, 0.57 g 4-(benzyloxy)-2-(chloromethyl)-3-methylpyridine, prepd. in 5 steps from 2,3-dimethyl-4-nitropyridine 1-oxide, was condensed with 5-methoxy-2-mercaptobenzimidazole to give 0.58 g (pyridylmethyl)thiobenzimidazole II. In rats 0.5 µmol II/kg i.v. reduced gastric secretion 82%.

IT 102126-99-8P 102127-00-4P 102127-01-5P
102127-02-6P 102127-03-7P 102127-04-8P
102127-05-9P 102127-06-0P 102127-07-1P
102127-08-2P 102127-09-3P 102127-10-6P
102127-11-7P 102127-12-8P 102127-13-9P
102127-14-0P 102127-15-1P 102127-16-2P
102127-18-4P 102127-21-9P 102127-22-0P
102127-23-1P 102127-24-2P 102127-25-3P
102127-26-4P 102127-27-5P 102127-28-6P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); **PREP** (Preparation); USES (Uses)
 (prepn. of, as antiulcer agent)


RN 102126-99-8 HCAPLUS

CN 1H-Benzimidazole, 2-[[[3-methyl-4-(phenylmethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 102127-00-4 HCAPLUS


CN 1H-Benzimidazole, 5-methoxy-2-[[[3-methyl-4-(phenylmethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 102127-01-5 HCAPLUS
 CN 1H-Benzimidazole, 2-[[[3-methyl-4-(phenylmethoxy)-2-pyridinyl]methyl]sulfinyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 102127-02-6 HCAPLUS
 CN 1H-Benzimidazole, 5-methyl-2-[[[3-methyl-4-(phenylmethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 102127-03-7 HCAPLUS
 CN 1H-Benzimidazol-5-amine, 6-bromo-2-[[[3-methyl-4-(phenylmethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 102127-04-8 HCAPLUS
 CN 1H-Benzimidazole, 2-[[[4-[(4-methoxyphenyl)methoxy]-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 102127-05-9 HCAPLUS

CN 1H-Benzimidazole, 2-[[[4-[(3,5-dichlorophenyl)methoxy]-3-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 102127-06-0 HCAPLUS

CN 1H-Benzimidazole, 2-[[[4-[(3,5-dichlorophenyl)methoxy]-3-methyl-2-pyridinyl)methyl]sulfinyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 102127-07-1 HCAPLUS

CN 1H-Benzimidazole, 2-[[[4-[(4-fluorophenyl)methoxy]-3-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 102127-08-2 HCAPLUS


CN 1H-Benzimidazole, 2-[[[4-[(4-fluorophenyl)methoxy]-3-methyl-2-pyridinyl)methyl]sulfinyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 102127-09-3 HCAPLUS
CN 1H-Benzimidazole, 5-chloro-2-[[[4-[(4-fluorophenyl)methoxy]-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 102127-10-6 HCAPLUS
CN 1H-Benzimidazole, 2-[[[4-[(4-chlorophenyl)methoxy]-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 102127-11-7 HCAPLUS
CN 1H-Benzimidazole, 2-[[[4-(phenylmethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 102127-12-8 HCAPLUS
CN 1H-Benzimidazole, 5-chloro-2-[[[4-[(4-chlorophenyl)methoxy]-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 102127-13-9 HCAPLUS
CN 1H-Benzimidazole, 5-chloro-2-[[[4-[(3,5-dichlorophenyl)methoxy]-3-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 102127-14-0 HCAPLUS
CN 1H-Benzimidazole, 2-[[[4-(phenylmethoxy)-2-pyridinyl]methyl]sulfinyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 102127-15-1 HCAPLUS
CN 1H-Benzimidazole, 2-[[[4-(2-phenylethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 102127-16-2 HCAPLUS
 CN 1H-Benzimidazole, 5-chloro-2-[[[4-(phenylmethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 102127-18-4 HCAPLUS
 CN 1H-Benzimidazole, 2-[[[4-[(4-fluorophenyl)methoxy]-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 102127-21-9 HCAPLUS
 CN 1H-Benzimidazole, 2-[[[5-methyl-4-(phenylmethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 102127-22-0 HCAPLUS
 CN 1H-Benzimidazole, 5-methoxy-2-[[[5-methyl-4-(phenylmethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 102127-23-1 HCAPLUS

CN Methanone, [2-[[[4-[(4-chlorophenyl)methoxy]-3-methyl-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol-5-yl]cyclopropyl- (9CI) (CA INDEX NAME)




RN 102127-24-2 HCAPLUS

CN 1H-Benzimidazole, 5-chloro-2-[[[5-methyl-4-(phenylmethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 102127-25-3 HCAPLUS

CN 1H-Benzimidazole, 2-[[[5-methyl-4-(phenylmethoxy)-2-pyridinyl]methyl]sulfinyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 102127-26-4 HCAPLUS

CN 1H-Benzimidazole, 2-[[[4-[(4-fluorophenyl)methoxy]-5-methyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 102127-27-5 HCAPLUS

CN 1H-Benzimidazole, 2-[[[4-[(4-fluorophenyl)methoxy]-5-methyl-2-pyridinyl)methyl]sulfinyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 102127-28-6 HCAPLUS

CN 1H-Benzimidazole, 5-methyl-2-[[[5-methyl-4-(phenylmethoxy)-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




IT 102127-32-2

RL: RCT (Reactant)
(redn. of)

RN 102127-32-2 HCAPLUS

CN 1H-Benzimidazole, 5-bromo-2-[[[3-methyl-4-(phenylmethoxy)-2-pyridinyl)methyl]thio]-6-nitro- (9CI) (CA INDEX NAME)




L11 ANSWER 58 OF 69 HCAPLUS COPYRIGHT 2002 ACS

Full Text Citing References

ACCESSION NUMBER: 1985:560504 HCAPLUS
DOCUMENT NUMBER: 103:160504
TITLE: Fluoroalkoxy compounds
INVENTOR(S): Senn-Bilfinger, Joerg; Schaeffer, Hartmann; Figala, Volker; Kurt, Klemm; Klemm, Kurt; Hartmann, Schaeffer; Et, Al.
PATENT ASSIGNEE(S): Byk-Gulden Lomberg Chemische Fabrik G.m.b.H., Fed. Rep. Ger.
SOURCE: S. African, 51 pp.
CODEN: SFXAB
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>ZA 8403288</u>	A	19841224	<u>ZA 1984-3288</u>	19840503
<u>IL 71664</u>	A1	19871130	<u>IL 1984-71664</u>	19840427
<u>HU 195220</u>	B	19880428	<u>HU 1986-4147</u>	19840427
<u>AU 8427500</u>	A1	19841108	<u>AU 1984-27500</u>	19840430
<u>AU 579316</u>	B2	19881124		
<u>DK 8402171</u>	A	19841104	<u>DK 1984-2171</u>	19840501
<u>US 4555518</u>	A	19851126	<u>US 1984-606872</u>	19840501
<u>NO 8401754</u>	A	19841105	<u>NO 1984-1754</u>	19840502
<u>JP 59206379</u>	A2	19841122	<u>JP 1984-87967</u>	19840502
<u>JP 05072391</u>	B4	19931012		
<u>FI 8401759</u>	A	19841104	<u>FI 1984-1759</u>	19840503
<u>EP 134400</u>	A2	19850320	<u>EP 1984-104993</u>	19840503
<u>EP 134400</u>	A3	19851211		
<u>EP 134400</u>	B1	19930324		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
<u>ES 532149</u>	A1	19860301	<u>ES 1984-532149</u>	19840503
<u>AT 87311</u>	E	19930415	<u>AT 1984-104993</u>	19840503
<u>ES 545145</u>	A1	19860116	<u>ES 1985-545145</u>	19850712
<u>JP 05086037</u>	A2	19930406	<u>JP 1992-65838</u>	19920324
<u>JP 05087508</u>	B4	19931216		
PRIORITY APPLN. INFO.:			CH 1983-2401	19830503
			EP 1984-104993	19840503
GI				




AB [(Pyridylmethyl)thio(sulfinyl)]benzimidazoles I (R = fluoroalkyl, ClF2C; R1 = H, alkyl, fluoroalkoxy, halo; R2, R4 = H, alkyl; R3 = H, alkyl, alkoxy; n = 0,1) were prepd. Thus, 4-F3COC6H3(NH2)2-1,2 cyclocondensed with EtOCS2K to give 5-methoxy-1H-benzimidazole-2-thiol. This was alkylated with 2-(chloromethyl)-4-methoxypyridine-HCl, prepd. by treating 4-methoxy-2-pyridinemethanol with SOCl2, to give I (R = F3C, R1 = R2 = R4 = H, R3 = MeO, n = 0). This was **oxidized** with 3-ClC6H4C(O)OOH to give I (n = 1, R-R4 as given) (II). In rats II inhibited ulcer formation with an ED50 of 0.6 mg/kg orally and, at the same dose, gave a 32% redn. in gastric acid secretion.

IT 97963-54-7P 97963-93-4P 97963-94-5P
97963-95-6P 97963-96-7P 97963-97-8P
97963-98-9P 97963-99-0P 97964-00-6P
97964-01-7P 97964-02-8P 97964-03-9P
97964-04-0P 97964-05-1P 97964-06-2P
97964-07-3P 97964-08-4P 97964-09-5P
97964-10-8P 97983-53-4P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); **PREP (Preparation)** (prepn. and antiulcer activity of)


RN 97963-54-7 HCAPLUS

CN 1H-Benzimidazole, 2-[[4-methoxy-2-pyridinyl)methyl]sulfinyl]-5-(1,1,2,2-tetrafluoroethoxy)-, sodium salt (9CI) (CA INDEX NAME)




Na


RN 97963-93-4 HCAPLUS
CN 1H-Benzimidazole, 2-[[4-methoxy-2-pyridinyl)methyl]sulfinyl]-5-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 97963-94-5 HCAPLUS
CN 1H-Benzimidazole, 2-[[4-methoxy-3-methyl-2-pyridinyl)methyl]sulfinyl]-5-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 97963-95-6 HCAPLUS
CN 1H-Benzimidazole, 2-[[4-methoxy-5-methyl-2-pyridinyl)methyl]sulfinyl]-5-(trifluoromethoxy)- (9CI) (CA INDEX NAME)



RN 97963-96-7 HCAPLUS
CN 1H-Benzimidazole, 2-[[4-methoxy-2-pyridinyl)methyl]sulfinyl]-5-(1,1,2,2-tetrafluoroethoxy)- (9CI) (CA INDEX NAME)




RN 97963-97-8 HCAPLUS
CN 1H-Benzimidazole, 2-[[4-methoxy-3-methyl-2-pyridinyl)methyl]sulfinyl]-5-(1,1,2,2-tetrafluoroethoxy)- (9CI) (CA INDEX NAME)




RN 97963-98-9 HCAPLUS

CN 1H-Benzimidazole, 2-[[4-methoxy-5-methyl-2-pyridinyl)methyl]sulfinyl]-5-(1,1,2,2-tetrafluoroethoxy)- (9CI) (CA INDEX NAME)




RN 97963-99-0 HCAPLUS

CN 1H-Benzimidazole, 2-[[3-methyl-2-pyridinyl)methyl]sulfinyl]-5-(1,1,2,2-tetrafluoroethoxy)- (9CI) (CA INDEX NAME)




RN 97964-00-6 HCAPLUS

CN 1H-Benzimidazole, 2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-5-(1,1,2,2-tetrafluoroethoxy)- (9CI) (CA INDEX NAME)




RN 97964-01-7 HCAPLUS

CN 1H-Benzimidazole, 2-[[4-methoxy-2-pyridinyl)methyl]sulfinyl]-5-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)




RN 97964-02-8 HCAPLUS

CN 1H-Benzimidazole, 2-[[4-methoxy-3-methyl-2-pyridinyl)methyl]sulfinyl]-5-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)




RN 97964-03-9 HCAPLUS

CN 1H-Benzimidazole, 5-(chlorodifluoromethoxy)-2-[[4-methoxy-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 97964-04-0 HCAPLUS

CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[4-methoxy-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 97964-05-1 HCAPLUS

CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[4-methoxy-3-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 97964-06-2 HCAPLUS

CN 1H-Benzimidazole, 5,6-bis(difluoromethoxy)-2-[[4-methoxy-3-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 97964-07-3 HCAPLUS

CN 1H-Benzimidazole, 5,6-bis(difluoromethoxy)-2-[[4-methoxy-3-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 97964-08-4 HCAPLUS

CN 1H-Benzimidazole, 5-(difluoromethoxy)-6-fluoro-2-[[4-methoxy-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 97964-09-5 HCAPLUS

CN 1H-Benzimidazole, 5-(difluoromethoxy)-6-methoxy-2-[[4-methoxy-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 97964-10-8 HCAPLUS

CN 1H-Benzimidazole, 5-(difluoromethoxy)-6-methoxy-2-[[4-methoxy-3-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 97983-53-4 HCAPLUS

CN 1H-Benzimidazole, 2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-5-(trifluoromethoxy)- (9CI) (CA INDEX NAME)



IT 97963-57-0P 97963-58-1P 97964-11-9P

97964-12-0P 97964-13-1P 97964-14-2P

97964-15-3P 97964-16-4P 97964-17-5P

97964-18-6P 97964-19-7P 97964-20-0P

97964-21-1P 97964-22-2P 97964-23-3P

97964-24-4P 97964-25-5P 97964-26-6P


97964-27-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)

(prepn., oxidn., and antiulcer activity of)


RN 97963-57-0 HCAPLUS

CN 1H-Benzimidazole, 5-(difluoromethoxy)-6-methoxy-2-[[(4-methoxy-2-pyridinyl)methyl]thio]- (9CI) (CA INDEX NAME)




RN 97963-58-1 HCAPLUS

CN 1H-Benzimidazole, 5-(difluoromethoxy)-6-methoxy-2-[[(4-methoxy-3-methyl-2-pyridinyl)methyl]thio]- (9CI) (CA INDEX NAME)




RN 97964-11-9 HCAPLUS

CN 1H-Benzimidazole, 2-[[(4-methoxy-2-pyridinyl)methyl]thio]-5-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 97964-12-0 HCAPLUS

CN 1H-Benzimidazole, 2-[[(4-methoxy-3-methyl-2-pyridinyl)methyl]thio]-5-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 97964-13-1 HCAPLUS

CN 1H-Benzimidazole, 2-[[(4-methoxy-5-methyl-2-pyridinyl)methyl]thio]-5-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 97964-14-2 HCAPLUS

CN 1H-Benzimidazole, 2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-5-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 97964-15-3 HCAPLUS

CN 1H-Benzimidazole, 2-[[4-methoxy-2-pyridinyl)methyl]thio]-5-(1,1,2,2-tetrafluoroethoxy)- (9CI) (CA INDEX NAME)




RN 97964-16-4 HCAPLUS

CN 1H-Benzimidazole, 2-[[4-methoxy-3-methyl-2-pyridinyl)methyl]thio]-5-(1,1,2,2-tetrafluoroethoxy)- (9CI) (CA INDEX NAME)




RN 97964-17-5 HCAPLUS

CN 1H-Benzimidazole, 2-[[4-methoxy-5-methyl-2-pyridinyl)methyl]thio]-5-(1,1,2,2-tetrafluoroethoxy)- (9CI) (CA INDEX NAME)




RN 97964-18-6 HCAPLUS

CN 1H-Benzimidazole, 2-[[3-methyl-2-pyridinyl)methyl]thio]-5-(1,1,2,2-tetrafluoroethoxy)- (9CI) (CA INDEX NAME)




RN 97964-19-7 HCAPLUS

CN 1H-Benzimidazole, 2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-5-(1,1,2,2-tetrafluoroethoxy)- (9CI) (CA INDEX NAME)




RN 97964-20-0 HCAPLUS

CN 1H-Benzimidazole, 2-[[(4-methoxy-2-pyridinyl)methyl]thio]-5-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)




RN 97964-21-1 HCAPLUS

CN 1H-Benzimidazole, 2-[[(4-methoxy-3-methyl-2-pyridinyl)methyl]thio]-5-(2,2,2-trifluoroethoxy)- (9CI) (CA INDEX NAME)




RN 97964-22-2 HCAPLUS

CN 1H-Benzimidazole, 5-(chlorodifluoromethoxy)-2-[[(4-methoxy-2-pyridinyl)methyl]thio]- (9CI) (CA INDEX NAME)




RN 97964-23-3 HCAPLUS

CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[(4-methoxy-2-pyridinyl)methyl]thio]- (9CI) (CA INDEX NAME)




RN 97964-24-4 HCAPLUS

CN 1H-Benzimidazole, 5-(difluoromethoxy)-2-[[(4-methoxy-3-methyl-2-pyridinyl)methyl]thio]- (9CI) (CA INDEX NAME)




RN 97964-25-5 HCAPLUS


CN 1H-Benzimidazole, 5,6-bis(difluoromethoxy)-2-[[(4-methoxy-2-pyridinyl)methyl]thio]- (9CI) (CA INDEX NAME)



RN 97964-26-6 HCAPLUS
CN 1H-Benzimidazole, 5,6-bis(difluoromethoxy)-2-[[4-methoxy-3-methyl-2-pyridinyl)methyl]thio]- (9CI) (CA INDEX NAME)



RN 97964-27-7 HCAPLUS
CN 1H-Benzimidazole, 5-(difluoromethoxy)-6-fluoro-2-[[4-methoxy-2-pyridinyl)methyl]thio]- (9CI) (CA INDEX NAME)




L11 ANSWER 59 OF 69 HCAPLUS COPYRIGHT 2002 ACS

Full Text Citing References

ACCESSION NUMBER: 1985:62236 HCAPLUS
DOCUMENT NUMBER: 102:62236
TITLE: Acylated benzimidazoles, their use, and a pharmaceutical containing them
INVENTOR(S): Rainer, Georg; Riedel, Richard; Senn-Bilfinger, Joerg; Klemm, Kurt; Schaefer, Hartmann; Figala, Volker
PATENT ASSIGNEE(S): Byk-Gulden Lomberg Chemische Fabrik G.m.b.H., Fed. Rep. Ger.
SOURCE: Ger. Offen., 36 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3415971	A1	19841108	DE 1984-3415971	19840428
PRIORITY APPLN. INFO.: GI			CH 1983-2400	19830503



AB Acyl[(pyridylmethyl)thio/sulfinyl]benzimidazoles I [R = (un)substituted cycloalkyl, Ph; R1, R3 = H, alkyl; R2 = H, alkyl, alkoxy; n = 0, 1] were


prepd. Thus, cyclopropyl p-methoxyphenyl ketone was nitrated and treated with NH₃ to give 4-amino-3-nitrophenyl cyclopropyl ketone. This was hydrogenated to the diamine and cyclocondensed with EtOCS₂K to give 5-(cyclopropylcarbonyl)-1H-benzimidazole-2-thiol. This was alkylated with 2-(chloromethyl)-4-methoxypyridine-HCl to give 85% I (R = cyclopropyl, R₁ = R₃ = H, R₂ = MeO, n = 0) which was **oxidized** with 3-ClC₆H₄CO₃H to give 88% I (n = 1, R-R₃ as before) (II). In rats II inhibited gastric acid secretion and had antiulcer activity with and ED₅₀ <3.0 mg/kg orally.

IT 94452-40-1P 94452-41-2P 94452-43-4P
94452-46-7P 94452-51-4P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); **PREP (Preparation)**
 (prepn. and antiulcer activity of)


RN 94452-40-1 HCAPLUS

CN Methanone, cyclopropyl[2-[[4-methoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 94452-41-2 HCAPLUS

CN Methanone, cyclopropyl[2-[[4-methoxy-3-methyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 94452-43-4 HCAPLUS

CN Methanone, cyclopropyl[2-[[3-methyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 94452-46-7 HCAPLUS

CN Methanone, cyclopentyl[2-[[4-methoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)



RN 94452-51-4 HCAPLUS

CN Methanone, [2-[[4-methoxy-3-methyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazol-5-yl]phenyl]- (9CI) (CA INDEX NAME)




IT 94452-55-8P 94452-56-9P 94452-57-0P
94452-61-6P 94452-62-7P 94452-63-8P
94452-64-9P 94472-32-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP
 (Preparation)
 (prepn. and oxidn. of)


RN 94452-55-8 HCAPLUS

CN Methanone, cyclopropyl[2-[[4-methoxy-5-methyl-2-pyridinyl)methyl]thio]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 94452-56-9 HCAPLUS

CN Methanone, cyclopropyl[2-[[3-methyl-2-pyridinyl)methyl]thio]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 94452-57-0 HCAPLUS

CN Methanone, cyclopropyl[2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 94452-61-6 HCAPLUS

CN Methanone, cyclopentyl[2-[[4-methoxy-2-pyridinyl)methyl]thio]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 94452-62-7 HCAPLUS

CN Methanone, cyclopentyl[2-[[(4-methoxy-3-methyl-2-pyridinyl)methyl]thio]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 94452-63-8 HCAPLUS

CN Methanone, [2-[[(4-methoxy-2-pyridinyl)methyl]thio]-1H-benzimidazol-5-yl]phenyl- (9CI) (CA INDEX NAME)




RN 94452-64-9 HCAPLUS

CN Methanone, [2-[[(4-methoxy-3-methyl-2-pyridinyl)methyl]thio]-1H-benzimidazol-5-yl]phenyl- (9CI) (CA INDEX NAME)



RN 94472-32-9 HCAPLUS

CN Methanone, (4-fluorophenyl)[2-[[(4-methoxy-2-pyridinyl)methyl]thio]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




IT 94452-42-3P 94452-44-5P 94452-48-9P

94452-49-0P 94452-50-3P


RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 94452-42-3 HCAPLUS


CN Methanone, cyclopropyl[2-[[(4-methoxy-5-methyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 94452-44-5 HCAPLUS
CN Methanone, cyclopropyl[2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 94452-48-9 HCAPLUS
CN Methanone, cyclopentyl[2-[[4-methoxy-3-methyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)



RN 94452-49-0 HCAPLUS
CN Methanone, [2-[[4-methoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazol-5-yl]phenyl- (9CI) (CA INDEX NAME)




RN 94452-50-3 HCAPLUS
CN Methanone, (4-fluorophenyl)[2-[[4-methoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




IT 94452-53-6P 94452-54-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP
(Preparation)
(prepn., oxidn., and antiulcer activity of)

RN 94452-53-6 HCAPLUS
CN Methanone, cyclopropyl[2-[[4-methoxy-2-pyridinyl)methyl]thio]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)



RN 94452-54-7 HCAPLUS
 CN Methanone, cyclopropyl[2-[[(4-methoxy-3-methyl-2-pyridinyl)methyl]thio]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)



L11 ANSWER 60 OF 69 HCAPLUS COPYRIGHT 2002 ACS

Full Text Citing References


ACCESSION NUMBER: 1984:630546 HCAPLUS
 DOCUMENT NUMBER: 101:230546
 TITLE: Benzimidazole derivatives and their use
 INVENTOR(S): Braendstroem, Arne Elof; Carlsson, Stig Aake Ingemar; Kaelsson, Britt Inger Monica; Lindberg, Per Lennart
 PATENT ASSIGNEE(S): Aktiebolag Haessle, Swed.
 SOURCE: Ger. Offen., 109 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3404610	A1	19840816	DE 1984-3404610	19840209
SE 8400688	A	19840812	SE 1984-688	19840209
BE 898880	A1	19840810	BE 1984-212366	19840210
DK 8400591	A	19840812	DK 1984-591	19840210
FI 8400547	A	19840812	FI 1984-547	19840210
NO 8400504	A	19840813	NO 1984-504	19840210
GB 2134523	A1	19840815	GB 1984-3540	19840210
GB 2134523	B2	19870812		
AU 8424456	A1	19840816	AU 1984-24456	19840210
AU 578891	B2	19881110		
NL 8400446	A	19840903	NL 1984-446	19840210
ZA 8401011	A	19840926	ZA 1984-1011	19840210
FR 2543551	A1	19841005	FR 1984-2093	19840210
FR 2543551	B1	19870821		
JP 59181277	A2	19841015	JP 1984-22067	19840210
AT 8400435	A	19880315	AT 1984-435	19840210
AT 386825	B	19881025		
CH 666892	A	19880831	CH 1984-660	19840210
GB 2174988	A1	19861119	GB 1986-10790	19860502
GB 2174988	B2	19870826		
SE 8700498	A	19870210	SE 1987-498	19870210
SE 8700499	A	19870210	SE 1987-499	19870210
NO 8802001	A	19840813	NO 1988-2001	19880506
US 5039806	A	19910813	US 1989-408719	19890918

PRIORITY APPLN. INFO.:

SE 1983-736	19830211
US 1984-578418	19840209
GB 1984-3540	19840210
NO 1984-504	19840210
US 1986-884863	19860716
US 1987-21992	19870305
US 1988-266330	19881101
US 1989-379703	19890712

GI




AB Pyridinylmethylthio(or sulfinyl)benzimidazoles I [R - R3 = H, halo, cyano, F3C, NO2, CHO, modified CHO, alkyl, alkoxy, acyl, acyloxy, aryl, aryloxy, alkylthio, alkylsulfinyl; R4 = H, alkenyloxy, alkynyloxy, oxacycloalkyl, (un)substituted alkyl, alkoxy; n = 0,1] and their carbocyclic and heterocyclic fused-ring derivs. were prepd. Thus, 4-(allyloxy)-2,3,5-trimethylpyridine N-oxide was rearranged by heating in Ac2O to give 4-(allyloxy)-3,5-dimethyl-2-pyridinemethanol. This was converted to the 2-(chloromethyl) deriv. by SOCl2 and condensed with 4,5,6,7-tetramethyl-1H-benzimidazole-2-thiol to give I (R - R3 = R6 = R8 = Me, R4 = R5 = H, R7 = H2C:CHCH2O). I are effective in vitro inhibitors of secretion by rabbit gastric mucosa with -log molar IC50 4.5-6.7.

IT 73590-60-0

RL: RCT (Reactant)
(acylation of)

RN 73590-60-0 HCAPLUS

CN 1H-Benzimidazole, 2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-
(9CI) (CA INDEX NAME)




IT 73590-85-9

RL: RCT (Reactant)
(benzoylation of)

RN 73590-85-9 HCAPLUS

CN 1H-Benzimidazole, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]- (9CI) (CA INDEX NAME)




IT 92893-82-8P 92893-84-0P 92893-86-2P
92893-97-5P 92894-02-5P 92894-04-7P
92894-06-9P 92894-08-1P 92894-10-5P

92894-11-6P 92894-13-8P 92894-22-9P
92894-24-1P 92894-26-3P 92894-28-5P
92894-30-9P 92894-32-1P 92894-34-3P
92894-36-5P 92894-46-7P 92894-49-0P
92894-51-4P 92894-56-9P 92894-58-1P
92894-65-0P 92894-67-2P 92894-69-4P
92894-71-8P 92894-73-0P 92894-75-2P
92894-77-4P 92894-79-6P 92894-81-0P
92894-84-3P 92894-86-5P 92894-87-6P
92894-92-3P 92894-94-5P 92894-96-7P
92894-98-9P 92895-00-6P 92895-04-0P
92895-05-1P 92895-11-9P 92895-13-1P
92895-15-3P 92895-17-5P 92895-19-7P
92895-21-1P 92895-23-3P 92895-25-5P
92895-28-8P 92895-30-2P 92895-32-4P
92911-91-6P 92911-92-7P

RL: SPN (Synthetic preparation); **PREP (Preparation)**
 (prepn. and stomach antisecretory activity of)


RN 92893-82-8 HCAPLUS

CN 1H-Benzimidazole, 5-cyclohexyl-2-[[(5-ethyl-4-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 92893-84-0 HCAPLUS

CN 1H-Benzimidazole, 5-cyclohexyl-2-[[[4-(2-methoxyethoxy)-3,5-dimethyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 92893-86-2 HCAPLUS

CN 1H-Benzimidazole, 2-[[[3,5-dimethyl-4-[(tetrahydro-2-furanyl)methoxy]-2-pyridinyl]methyl]sulfinyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 92893-97-5 HCAPLUS

CN 2-Butanone, 4-[2-[[[3,5-dimethyl-4-(2-propenyloxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 92894-02-5 HCAPLUS

CN 1H-Benzimidazole, 2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-5-phenoxy]- (9CI) (CA INDEX NAME)




RN 92894-04-7 HCAPLUS

CN 1H-Benzimidazole, 2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-5-(2-phenylethoxy)- (9CI) (CA INDEX NAME)




RN 92894-06-9 HCAPLUS

CN Methanone, [2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazol-5-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 92894-08-1 HCAPLUS

CN 1H-Benzimidazole, 2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-5-phenyl]- (9CI) (CA INDEX NAME)




RN 92894-10-5 HCAPLUS

CN 1H-Benzimidazole, 2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-5-(methylsulfinyl)- (9CI) (CA INDEX NAME)




RN 92894-11-6 HCAPLUS

CN 1H-Benzimidazole, 2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-5-nitro- (9CI) (CA INDEX NAME)




RN 92894-13-8 HCAPLUS

CN 1H-Benzimidazole, 5-bromo-2-[[[3,5-dimethyl-4-(2-propenyloxy)-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 92894-22-9 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[[[(5-ethyl-4-methoxy-2-pyridinyl)methyl]sulfinyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 92894-24-1 HCAPLUS

CN 1H-Benzimidazole, 2-[[[(3,4-dimethyl-2-pyridinyl)methyl]sulfinyl]-4,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 92894-26-3 HCAPLUS

CN 1H-Benzimidazole, 2-[[[(4,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-4,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 92894-28-5 HCAPLUS

CN 1H-Benzimidazole, 2-[[[(3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-4,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 92894-30-9 HCAPLUS

CN 1H-Benzimidazole, 2-[[[(3,4-dimethyl-2-pyridinyl)methyl]sulfinyl]-4,5,7-trimethyl- (9CI) (CA INDEX NAME)




RN 92894-32-1 HCAPLUS

CN 1H-Benzimidazole-5-carbonitrile, 2-[[[(4-ethoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 92894-34-3 HCAPLUS

CN 1H-Benzimidazole, 2-[[[(5-ethyl-4-methoxy-2-pyridinyl)methyl]sulfinyl]-5,6-dimethyl- (9CI) (CA INDEX NAME)




RN 92894-36-5 HCAPLUS

CN Piperidine, 1-[[2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazol-5-yl]carbonyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 92894-46-7 HCAPLUS

CN 1H-Benzimidazole, 2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-5-(3-phenoxypropoxy)- (9CI) (CA INDEX NAME)




RN 92894-49-0 HCAPLUS

CN 1H-Benzimidazole, 2-[[3,5-dimethyl-4-(2-propenyloxy)-2-pyridinyl)methyl]sulfinyl]-5-ethyl- (9CI) (CA INDEX NAME)




RN 92894-51-4 HCAPLUS

CN 1H-Benzimidazole, 2-[[3,5-dimethyl-4-(3-methylbutoxy)-2-pyridinyl)methyl]sulfinyl]-5-methoxy- (9CI) (CA INDEX NAME)




RN 92894-56-9 HCAPLUS

CN 1H-Benzimidazole, 5-(1,1-dimethylethyl)-2-[[3,5-dimethyl-4-(2-propenyloxy)-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 92894-58-1 HCAPLUS

CN 1H-Benzimidazole, 2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-5-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 92894-65-0 HCAPLUS

CN 1H-Benzimidazole, 2-[[[3,5-dimethyl-4-[(tetrahydro-2-furanyl)methoxy]-2-pyridinyl)methyl]sulfinyl]-5-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 92894-67-2 HCAPLUS

CN 1H-Benzimidazole, 2-[[[4,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-5-(2-methoxyethoxy)-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 92894-69-4 HCAPLUS

CN Ethanone, 1-[2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-4,6-dimethyl-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 92894-71-8 HCAPLUS

CN Ethanone, 1-[2-[[[3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-4,6-dimethyl-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 92894-73-0 HCAPLUS

CN 1-Propanone, 1-[2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-4,6-dimethyl-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 92894-75-2 HCAPLUS

CN 1H-Benzimidazole, 5-ethyl-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 92894-77-4 HCAPLUS

CN 1H-Benzimidazole, 5-ethyl-2-[[[4-methoxy-3-methyl-2-pyridinyl)methyl]sulfinyl]-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 92894-79-6 HCAPLUS

CN 1H-Benzimidazole-5-carbonitrile, 4,6-diethyl-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 92894-81-0 HCAPLUS

CN 1H-Benzimidazole, 5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-4,6,7-trimethyl- (9CI) (CA INDEX NAME)




RN 92894-84-3 HCAPLUS

CN 1H-Benzimidazole, 2-[[[3,5-dimethyl-4-(2-propenyloxy)-2-pyridinyl)methyl]sulfinyl]-5-methoxy- (9CI) (CA INDEX NAME)




RN 92894-86-5 HCAPLUS

CN 1H-Benzimidazole, 2-[[[3,5-dimethyl-4-(2-propynyloxy)-2-pyridinyl]methyl]sulfinyl]-5-methoxy- (9CI) (CA INDEX NAME)




RN 92894-87-6 HCAPLUS

CN 1H-Benzimidazole, 2-[[[5-ethyl-4-methoxy-2-pyridinyl]methyl]sulfinyl]-5-methoxy- (9CI) (CA INDEX NAME)




RN 92894-92-3 HCAPLUS

CN 1H-Benzimidazole, 2-[[[3,5-dimethyl-4-(2-propenyloxy)-2-pyridinyl]methyl]sulfinyl]-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 92894-94-5 HCAPLUS

CN Acetonitrile, [[2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol-5-yl]oxy]- (9CI) (CA INDEX NAME)




RN 92894-96-7 HCAPLUS

CN 1H-Benzimidazole, 5-cyclohexyl-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl]methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 92894-98-9 HCAPLUS

CN 1H-Benzimidazole-5-methanol, 2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 92895-00-6 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[[[3,5-dimethyl-4-(2-propenyloxy)-2-pyridinyl)methyl]sulfinyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 92895-04-0 HCAPLUS

CN 1H-Benzimidazole, 2-[[[3,4-dimethyl-2-pyridinyl)methyl]sulfinyl]-5-methoxy-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 92895-05-1 HCAPLUS

CN 1H-Benzimidazole, 5-(heptyloxy)-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 92895-11-9 HCAPLUS

CN 1H-Benzimidazole, 5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 92895-13-1 HCAPLUS

CN 1H-Benzimidazole, 2-[[[3,5-dimethyl-4-(2-propenyloxy)-2-pyridinyl]methyl]sulfinyl]-4,5,6,7-tetramethyl- (9CI) (CA INDEX NAME)




RN 92895-15-3 HCAPLUS

CN 1H-Benzimidazole, 2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-4,5,6,7-tetramethyl- (9CI) (CA INDEX NAME)




RN 92895-17-5 HCAPLUS

CN 1H-Benzimidazole, 2-[[[3,5-dimethyl-4-(2-propenyloxy)-2-pyridinyl]methyl]sulfinyl]-4,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 92895-19-7 HCAPLUS

CN 1H-Benzimidazole, 2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-4,5,6-trimethyl- (9CI) (CA INDEX NAME)




RN 92895-21-1 HCAPLUS

CN 1H-Benzimidazole, 2-[[[3,5-dimethyl-4-(2-propenyloxy)-2-pyridinyl]methyl]sulfinyl]-4,5,7-trimethyl- (9CI) (CA INDEX NAME)




RN 92895-23-3 HCAPLUS

CN 1H-Benzimidazole, 2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-4,5,7-trimethyl- (9CI) (CA INDEX NAME)




RN 92895-25-5 HCAPLUS

CN 1H-Benzimidazole, 2-[[[3,5-dimethyl-4-(2-propenyloxy)-2-pyridinyl)methyl]sulfinyl]-4,5-dimethyl- (9CI) (CA INDEX NAME)




RN 92895-28-8 HCAPLUS

CN 1H-Benzimidazole, 2-[[[3,5-dimethyl-4-(2-propenyloxy)-2-pyridinyl)methyl]sulfinyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 92895-30-2 HCAPLUS

CN 1H-Benzimidazole, 2-[[[3,5-dimethyl-4-(2-propenyloxy)-2-pyridinyl)methyl]sulfinyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 92895-32-4 HCAPLUS


CN 1H-Benzimidazole, 2-[[[3,5-dimethyl-4-(2-propenyloxy)-2-pyridinyl)methyl]sulfinyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 92911-91-6 HCAPLUS
CN 1H-Benzimidazole, 2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-5-(2-methoxyethoxy)-4,6-dimethyl- (9CI) (CA INDEX NAME)



RN 92911-92-7 HCAPLUS
CN 1H-Benzimidazole, 2-[[[3,5-dimethyl-4-(2-propenyloxy)-2-pyridinyl)methyl]sulfinyl]-5,6-dimethyl- (9CI) (CA INDEX NAME)



L11 ANSWER 61 OF 69 HCAPLUS COPYRIGHT 2002 ACS


Full Text Citing References

ACCESSION NUMBER: 1983:470734 HCAPLUS
DOCUMENT NUMBER: 99:70734
TITLE: Substituted benzimidazoles, their use and a drug containing them
INVENTOR(S): Senn-Bilfinger, Joerg; Schaefer, Hartmann; Figala, Volker; Klemm, Kurt; Rainer, Georg; Riedel, Richard; Schudt, Christian; Simon, Wolfgang
PATENT ASSIGNEE(S): Byk-Gulden Lomberg Chemische Fabrik G.m.b.H., Fed. Rep. Ger.
SOURCE: Ger. Offen., 31 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3240248	A1	19830601	DE 1982-3240248	19821030
US 4472409	A	19840918	US 1982-437883	19821029
EP 80602	A1	19830608	EP 1982-110054	19821030
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
FI 8203787	A	19830506	FI 1982-3787	19821104
DK 8204916	A	19830506	DK 1982-4916	19821105
NO 8203691	A	19830506	NO 1982-3691	19821105
AU 8290195	A1	19830512	AU 1982-90195	19821105
AU 544288	B2	19850523		
JP 58135881	A2	19830812	JP 1982-193582	19821105

<u>ZA 8208136</u>	A	19830928	<u>ZA 1982-8136</u>	19821105
<u>HU 30661</u>	O	19840328	<u>HU 1982-3570</u>	19821105
<u>HU 187521</u>	B	19860128		
<u>ES 517167</u>	A1	19860201	<u>ES 1982-517167</u>	19821105
<u>ES 526899</u>	A1	19850501	<u>ES 1983-526899</u>	19831028
<u>ES 526900</u>	A1	19851116	<u>ES 1983-526900</u>	19831028
PRIORITY APPLN. INFO.:			<u>CH 1981-7080</u>	19811105
			<u>CH 1981-7081</u>	19811105

GI



AB The title compds. (I; R = F3C; R1, R2 = H, Me; n = 0,1) were prepd. Thus, 4-(trifluoromethyl)-o-phenylenediamine was cyclocondensed with CS2 to give 5-(trifluoromethyl)-1H-benzimidazole-2-thiol. This was treated with 2-(chloromethyl)-4-methoxypyridine-HCl (prepd. by chlorination of 4-methoxy-2-pyridinemethanol with SOCl2) to give 59% I (R = 5-F3C, R1 = R2 = H, n = 0). This (0.3 g) was **oxidized** with 3-ClC6H4C(O)OOH to give 0.1 g I (R = 5-F3C, R1 = R2 = H, n = 1) (II). In rats, II had an antiulcer ED50 of 0.45 mg/kg orally, compared to 2.3 for omeprazol.


IT 86604-66-2P 86604-68-4P 86604-70-8P

86613-00-5P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); **PREP (Preparation)** (prepn. and antiulcer activity of)


RN 86604-66-2 HCAPLUS

CN 1H-Benzimidazole, 2-[[4-methoxy-2-pyridinyl)methyl]sulfinyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 86604-68-4 HCAPLUS

CN 1H-Benzimidazole, 2-[[4-methoxy-3-methyl-2-pyridinyl)methyl]sulfinyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 86604-70-8 HCAPLUS

CN 1H-Benzimidazole, 2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 86613-00-5 HCAPLUS

CN 1H-Benzimidazole, 2-[[4-methoxy-2-pyridinyl)methyl]sulfinyl]-5-(trifluoromethyl)-, sodium salt (9CI) (CA INDEX NAME)




Na

IT 86604-65-1P 86604-71-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and oxidn. of)


RN 86604-65-1 HCAPLUS

CN 1H-Benzimidazole, 2-[[4-methoxy-2-pyridinyl)methyl]thio]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 86604-71-9 HCAPLUS

CN 1H-Benzimidazole, 2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




IT 86604-64-0P 86604-91-3P 86604-92-4P

86604-93-5P 86612-99-9P 86613-01-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)


RN 86604-64-0 HCAPLUS

CN 1H-Benzimidazole, 2-[[4-methoxy-2-pyridinyl)methyl]sulfinyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 86604-91-3 HCAPLUS

CN 1H-Benzimidazole, 2-[[4-methoxy-3-methyl-2-pyridinyl)methyl]sulfinyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 86604-92-4 HCAPLUS

CN 1H-Benzimidazole, 2-[[4-methoxy-5-methyl-2-pyridinyl)methyl]sulfinyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 86604-93-5 HCAPLUS

CN 1H-Benzimidazole, 2-[[4-methoxy-5-methyl-2-pyridinyl)methyl]sulfinyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 86612-99-9 HCAPLUS


CN 1H-Benzimidazole, 2-[[4-methoxy-2-pyridinyl)methyl]sulfinyl]-5-(trifluoromethyl)-, calcium salt (9CI) (CA INDEX NAME)



1/2 Ca

RN 86613-01-6 HCAPLUS

CN 1H-Benzimidazole, 2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L11 ANSWER 62 OF 69 HCAPLUS COPYRIGHT 2002 ACS

Full Text Citing References


ACCESSION NUMBER: 1983:16689 HCAPLUS
 DOCUMENT NUMBER: 98:16689
 TITLE: Gastric acid secretion inhibiting substituted 2-(2-benzimidazolyl)pyridines, pharmaceutical preparations containing them and method for inhibiting gastric acid secretion
 INVENTOR(S): Junggren, Ulf K.; Sjostrand, Sven E.
 PATENT ASSIGNEE(S): Aktiebolag Haessle, Swed.
 SOURCE: Can., 27 pp. Division of Can. Appl. No. 325,188.
 CODEN: CAXXA4
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>CA 1129417</u>	A2	19820810	<u>CA 1981-386943</u>	19810929
<u>SE 7804231</u>	A	19791015	<u>SE 1978-4231</u>	19780414
<u>CA 1127158</u>	A1	19820706	<u>CA 1979-325188</u>	19790409
<u>US 4337257</u>	A	19820629	<u>US 1980-150965</u>	19800519
<u>DK 8204209</u>	A	19820922	<u>DK 1982-4209</u>	19820922
DK 151802	B	19880104		
DK 151802	C	19880613		
<u>AT 8301006</u>	A	19830915	<u>AT 1983-1006</u>	19830322
AT 374472	B	19840425		
<u>AT 8301007</u>	A	19830915	<u>AT 1983-1007</u>	19830322
AT 374473	B	19840425		
<u>AT 8301005</u>	A	19831215	<u>AT 1983-1005</u>	19830322
AT 375365	B	19840725		
<u>US 4508905</u>	A	19850402	<u>US 1983-482513</u>	19830406
<u>FI 8302220</u>	A	19830617	<u>FI 1983-2220</u>	19830617
FI 70214	B	19860228		
FI 70214	C	19860912		
<u>AT 8302904</u>	A	19890815	<u>AT 1983-2904</u>	19830811
AT 389995	B	19900226		
<u>AT 8901411</u>	A	19990715	<u>AT 1989-1411</u>	19890608
AT 406119	B	20000225		

PRIORITY APPLN. INFO.:

<u>SE 1978-4231</u>	19780414
<u>CA 1979-325188</u>	19790409
<u>US 1979-27277</u>	19790405
<u>DK 1979-1511</u>	19790411
<u>AT 1979-2732</u>	19790412
<u>FI 1979-1219</u>	19790412
<u>US 1980-150965</u>	19800519
<u>US 1982-369404</u>	19820419
<u>AT 1983-2904</u>	19830811

GI



AB Thirty 2-[(2-pyridylmethyl)sulfinyl]benzimidazoles (I; R = H, 4- or 5-Me, 5-Cl, 5-COMe, 2-CO₂Me, 5-CO₂Et or 5-OMe; R₁ = H or 6-Me; R₂ = H or Me; R₃, R₅ = H or Me; R₄ = H, Me, OMe, OEt or OCH₂CH₂OMe, n = 1) were prepd. by std. methods and were evaluated (in dogs) as gastric juice secretion inhibitors. Thus, [(5-acetyl-6-methyl-2-benzimidazolyl)sulfinyl]methyl lithium refluxed with 2-chloro-3,5-dimethylpyridine in benzene for 2 h gave 82% I (R = 5-COMe, R₁ = 6-Me, R₂ = R₄ = H, R₃ = R₅ = Me, n = 1), which effected 100% inhibition of gastric juice secretion in dogs at 2 μmol/kg s.c. The prepn. of 3 similar I (n = 0), i.e., thio rather than sulfinyl compds., is given and the prepn. of 23 addnl. I (n = 0) is claimed.


IT 73590-36-0P 73590-37-1P 73590-38-2P
73590-39-3P 73590-40-6P 73590-41-7P
73590-42-8P 73590-43-9P 73590-44-0P
73590-45-1P 73590-46-2P 73590-47-3P
73590-48-4P 73590-49-5P 73590-50-8P
73590-51-9P 73590-52-0P 73590-53-1P
73590-54-2P 73590-55-3P 73590-56-4P
73590-57-5P 73590-58-6P 73590-59-7P
73590-60-0P 73590-61-1P 73590-62-2P
73590-63-3P

RL: SPN (Synthetic preparation); **PREP (Preparation)**

(prepn. and gastric juice-secreting-inhibiting activity of)


RN 73590-36-0 HCAPLUS

CN Ethanone, 1-[2-[[[(4,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-6-methyl-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 73590-37-1 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[[[(4,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 73590-38-2 HCAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[[[(4,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 73590-39-3 HCAPLUS
CN Ethanone, 1-[2-[[3,4-dimethyl-2-pyridinyl)methyl]sulfinyl]-6-methyl-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 73590-40-6 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[[3,4-dimethyl-2-pyridinyl)methyl]sulfinyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 73590-41-7 HCAPLUS
CN 1H-Benzimidazole, 2-[[3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-4,6-dimethyl- (9CI) (CA INDEX NAME)



RN 73590-42-8 HCAPLUS
CN Ethanone, 1-[2-[[3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-6-methyl-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 73590-43-9 HCAPLUS
CN Ethanone, 1-[6-methyl-2-[[3,4,5-trimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 73590-44-0 HCAPLUS

CN Ethanone, 1-[2-[[[4-methoxy-2-pyridinyl)methyl]sulfinyl]-6-methyl-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 73590-45-1 HCAPLUS

CN 1H-Benzimidazole, 2-[[[4-methoxy-2-pyridinyl)methyl]sulfinyl]-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 73590-46-2 HCAPLUS

CN Ethanone, 1-[2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-6-methyl-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 73590-47-3 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[[[3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 73590-48-4 HCAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 6-methyl-2-[[[3,4,5-trimethyl-2-pyridinyl)methyl]sulfinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 73590-49-5 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[[4-methoxy-2-pyridinyl)methyl]sulfinyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 73590-50-8 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[[4-ethoxy-2-pyridinyl)methyl]sulfinyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 73590-51-9 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[[4-methoxy-3-methyl-2-pyridinyl)methyl]sulfinyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 73590-52-0 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 73590-53-1 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[[4-methoxy-5-methyl-2-pyridinyl)methyl]sulfinyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 73590-54-2 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[[[(3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 73590-55-3 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 73590-56-4 HCAPLUS
CN Ethanone, 1-[2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)



RN 73590-57-5 HCAPLUS
CN 1H-Benzimidazole, 5-methoxy-2-[[[(4-methoxy-5-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 73590-58-6 HCAPLUS
CN 1H-Benzimidazole, 5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 73590-59-7 HCAPLUS

CN 1H-Benzimidazole, 2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 73590-60-0 HCAPLUS

CN 1H-Benzimidazole, 2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 73590-61-1 HCAPLUS

CN 1H-Benzimidazole, 5-chloro-2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 73590-62-2 HCAPLUS

CN 1H-Benzimidazole, 2-[[4-(2-methoxyethoxy)-2-pyridinyl)methyl]sulfinyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 73590-63-3 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-, ethyl ester (9CI) (CA INDEX NAME)




IT 73590-65-5P 73590-70-2P 73590-72-4P

RL: **RCT (Reactant)**; SPN (Synthetic preparation); PREP
(Preparation)

(prepn. and oxidn. of)


RN 73590-65-5 HCAPLUS

CN Ethanone, 1-[2-[[[4,5-dimethyl-2-pyridinyl)methyl]thio]-6-methyl-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 73590-70-2 HCAPLUS

CN 1H-Benzimidazole, 2-[[[(3,5-dimethyl-2-pyridinyl)methyl]thio]-4,6-dimethyl- (9CI) (CA INDEX NAME)



RN 73590-72-4 HCAPLUS

CN Ethanone, 1-[6-methyl-2-[[[(3,4,5-trimethyl-2-pyridinyl)methyl]thio]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




IT 84006-12-2 84006-13-3 84006-14-4
84015-97-4

RL: **RCT (Reactant)**

(prepn. of pharmaceutical compns. contg.)

RN 84006-12-2 HCAPLUS


CN Ethanone, 1-[2-[[[4,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-6-methyl-1H-benzimidazol-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



HCl

RN 84006-13-3 HCAPLUS


CN Ethanone, 1-[2-[[[(3,4-dimethyl-2-pyridinyl)methyl]sulfinyl]-6-methyl-1H-benzimidazol-5-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



HCl

RN 84006-14-4 HCAPLUS

CN Ethanone, 1-[2-[[[3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-6-methyl-1H-benzimidazol-5-yl]-, hydrochloride (9CI) (CA INDEX NAME)



x HCl


RN 84015-97-4 HCAPLUS

CN Benzoic acid, 4-hydroxy-, compd. with 1-[2-[[[3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-6-methyl-1H-benzimidazol-5-yl]ethanone (9CI) (CA INDEX NAME)

CM 1

CRN 73590-42-8


CMF C18 H19 N3 O2 S



CM 2

CRN 99-96-7

CMF C7 H6 O3



L11 ANSWER 63 OF 69 HCAPLUS COPYRIGHT 2002 ACS

Full Text Citing References

ACCESSION NUMBER:

1982:68986 HCAPLUS

DOCUMENT NUMBER:

96:68986

TITLE:

Heterocyclic compounds useful for inducing stomach acid secretion


INVENTOR(S):

Berntsson, P. B.; Carlsson, S. A. I.; Garberg, L. E.; Junggren, U. K.; Sjostrand, S. E.; Von Wittken Sundell, G. W.

PATENT ASSIGNEE(S): Aktiebolag Hassle, Swed.
 SOURCE: Swed., 24 pp.
 CODEN: SSXXAY
 DOCUMENT TYPE: Patent
 LANGUAGE: Swedish
 FAMILY ACC. NUM. COUNT: 8
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>SE 416649</u>	B	19810126	<u>SE 1974-6513</u>	19740516
SE 416649	C	19810507		
<u>NO 143222</u>	B	19800922	<u>NO 1975-2851</u>	19750815
NO 143222	C	19810102		
NO 7502851	A	19770216		
<u>FI 63756</u>	B	19830429	<u>FI 1975-2327</u>	19750815
FI 63756	C	19830810		
FI 7502327	A	19770216		
<u>ZA 7506600</u>	A	19760929	<u>ZA 1975-6600</u>	19751020
<u>GB 1525958</u>	A	19780927	<u>GB 1975-43039</u>	19751020
<u>DE 2548340</u>	A1	19770505	<u>DE 1975-2548340</u>	19751029
DE 2548340	C2	19871203		
<u>CS 196289</u>	P	19800331	<u>CS 1975-7458</u>	19751105
<u>US 4045563</u>	A	19770830	<u>US 1975-630916</u>	19751111
<u>HU 172653</u>	P	19781128	<u>HU 1975-HE696</u>	19751112
<u>SU 602118</u>	D	19780405	<u>SU 1975-2189960</u>	19751113
<u>FR 2331340</u>	A1	19770610	<u>FR 1975-34910</u>	19751114
FR 2331340	B1	19790119		
<u>CA 1055033</u>	A1	19790522	<u>CA 1975-239643</u>	19751114
<u>CS 196290</u>	P	19800331	<u>CS 1978-6886</u>	19781023
<u>FI 8101747</u>	A	19810604	<u>FI 1981-1747</u>	19810604
FI 65617	B	19840229		
FI 65617	C	19840611		
PRIORITY APPLN. INFO.:			<u>SE 1974-6513</u>	19740516
			<u>FI 1975-2327</u>	19750815
			<u>CS 1975-7458</u>	19751105

GI




AB The sulfoxide I ($n = 1$; $X = \text{alkylene}$; $R, R1 = H, \text{alkyl, halogen, alkoxy carbonyl, acyl}$; $R2 = H, \text{alkyl, alkoxy carbonyl}$; $R3 = H, \text{alkyl, halogen}$) were prepd. Thus 28.9 g I ($n = 0, X = CH_2, R-R3 = H$) was **oxidized** with 3-ClC₆H₄CO₂OH to give 22.3 g I ($n = 1, X = CH_2, R-R3 = H$) which had an ED₅₀ against pentagastrin-induced stomach acid secretion in dogs of 0.5 mg/kg orally.

IT 23593-22-8P 57258-10-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and oxidn. of)

RN 23593-22-8 HCAPLUS

CN 1H-Benzimidazole, 2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)



RN 57258-10-3 HCAPLUS
CN 1H-Benzimidazole, 4-methyl-2-[(2-pyridinylmethyl)thio]-, monohydrochloride (9CI) (CA INDEX NAME)




HCl


IT 57237-97-5P 60524-78-9P 60524-79-0P
60524-80-3P 60524-81-4P 60524-83-6P
60524-87-0P 60524-88-1P 60524-89-2P
60524-90-5P 60524-91-6P 60524-97-2P
60524-98-3P 60524-99-4P 60525-00-0P
64588-68-7P 64588-75-6P 78242-93-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and stomach acid secretion-inhibiting activity of)


RN 57237-97-5 HCAPLUS
CN 1H-Benzimidazole, 2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-78-9 HCAPLUS
CN 1H-Benzimidazole, 4,6-dimethyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-79-0 HCAPLUS
CN 1H-Benzimidazole, 5-ethyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-80-3 HCAPLUS
CN 1H-Benzimidazole, 6-chloro-4-methyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-81-4 HCAPLUS
CN 1H-Benzimidazole, 5-methoxy-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-83-6 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(2-pyridinylmethyl)sulfinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 60524-87-0 HCAPLUS
CN 1H-Benzimidazole, 5-methyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-88-1 HCAPLUS
CN 1H-Benzimidazole, 5-chloro-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)



RN 60524-89-2 HCAPLUS
CN 1H-Benzimidazole, 5-(1-methylethyl)-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-90-5 HCAPLUS
CN 1H-Benzimidazole, 5-propyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-91-6 HCAPLUS

CN 1H-Benzimidazole, 5-methyl-2-[[(5-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-97-2 HCAPLUS

CN 1H-Benzimidazole, 2-[[(3-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-98-3 HCAPLUS

CN 1H-Benzimidazole, 2-[[(5-ethyl-2-pyridinyl)methyl]sulfinyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 60524-99-4 HCAPLUS

CN 1H-Benzimidazole, 2-[[(5-ethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 60525-00-0 HCAPLUS

CN 1H-Benzimidazole, 4-chloro-2-[(2-pyridinylmethyl) sulfinyl]- (9CI) (CA INDEX NAME)




RN 64588-68-7 HCAPLUS


CN 1H-Benzimidazole, 5-bromo-2-[(2-pyridinylmethyl) sulfinyl]- (9CI) (CA INDEX NAME)



RN 64588-75-6 HCAPLUS
CN 1H-Benzimidazole, 5-methyl-2-[[4-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 78242-93-0 HCAPLUS
CN 1H-Benzimidazole, 2-[[5-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




IT 60524-82-5P 60525-02-2P 64588-67-6P
64588-69-8P 71404-30-3P 78242-94-1P
78242-95-2P 78242-96-3P 78242-97-4P
78242-98-5P 78242-99-6P 78243-00-2P
78243-01-3P 78243-02-4P 78243-03-5P
78243-04-6P 78243-05-7P 78243-06-8P
78243-07-9P 78243-08-0P 78243-09-1P
78243-10-4P 78243-11-5P 78243-12-6P
78243-13-7P 78243-14-8P 78243-15-9P
78243-16-0P 78243-17-1P 78243-18-2P
78243-19-3P 78243-20-6P 78243-21-7P
78243-22-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 60524-82-5 HCAPLUS
CN Ethanone, 1-[2-[(2-pyridinylmethyl)sulfinyl]-1H-benzimidazol-5-yl]- (9CI)
(CA INDEX NAME)




RN 60525-02-2 HCAPLUS
CN 1H-Benzimidazole, 5,6-dimethyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 64588-67-6 HCAPLUS

CN 1H-Benzimidazole, 5-(1,1-dimethylethyl)-2-[[(5-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 64588-69-8 HCAPLUS

CN 1H-Benzimidazole, 5-(1-methylethyl)-2-[[(5-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 71404-30-3 HCAPLUS

CN 1H-Benzimidazole, 4,5-dimethyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 78242-94-1 HCAPLUS

CN 1H-Benzimidazole, 5-(1,1-dimethylethyl)-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 78242-95-2 HCAPLUS

CN 1H-Benzimidazole-5-carboxamide, N,N-dimethyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 78242-96-3 HCAPLUS


CN 1H-Benzimidazole, 4-methyl-2-[[(4-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 78242-97-4 HCAPLUS
CN 1H-Benzimidazole, 4,6-dimethyl-2-[[5-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 78242-98-5 HCAPLUS
CN 1-Propanone, 1-[2-[(2-pyridinylmethyl)sulfinyl]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 78242-99-6 HCAPLUS
CN 1-Propanone, 1-[2-[[5-methyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)



RN 78243-00-2 HCAPLUS
CN Ethanone, 1-[2-[[5-ethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 78243-01-3 HCAPLUS
CN 1H-Benzimidazole, 5-ethyl-2-[[5-ethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 78243-02-4 HCAPLUS
CN 1H-Benzimidazole, 2-[[5-ethyl-2-pyridinyl)methyl]sulfinyl]-5-methoxy-

(9CI) (CA INDEX NAME)




RN 78243-03-5 HCAPLUS

CN 1H-Benzimidazole, 5-methoxy-2-[[4-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 78243-04-6 HCAPLUS

CN 1H-Benzimidazole, 4,7-dimethyl-2-[(2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 78243-05-7 HCAPLUS

CN 1H-Benzimidazole, 4-methyl-2-[(5-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 78243-06-8 HCAPLUS

CN 1H-Benzimidazole, 5-chloro-6-methoxy-2-[(2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 78243-07-9 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(5-methyl-2-pyridinyl)methyl]sulfinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 78243-08-0 HCAPLUS

CN 1H-Benzimidazole, 5-methoxy-6-methyl-2-[(2-pyridinylmethyl) sulfinyl]- (9CI) (CA INDEX NAME)




RN 78243-09-1 HCAPLUS

CN Ethanone, 1-[6-methyl-2-[(2-pyridinylmethyl) sulfinyl]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 78243-10-4 HCAPLUS

CN Ethanone, 1-[6-methyl-2-[(5-methyl-2-pyridinyl)methyl] sulfinyl]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 78243-11-5 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 6-methyl-2-[(5-methyl-2-pyridinyl)methyl] sulfinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 78243-12-6 HCAPLUS


CN 1H-Benzimidazole-4-carboxylic acid, 2-[(2-pyridinylmethyl) sulfinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 78243-13-7 HCAPLUS


CN 1H-Benzimidazole, 4-ethyl-2-[(5-methyl-2-pyridinyl)methyl] sulfinyl]- (9CI) (CA INDEX NAME)

(9CI) (CA INDEX NAME)




RN 78243-14-8 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 7-methyl-2-[[5-methyl-2-pyridinyl)methyl]sulfinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 78243-15-9 HCAPLUS

CN Ethanone, 1-[4-methyl-2-[[5-methyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 78243-16-0 HCAPLUS

CN Ethanone, 1-[6-methyl-2-[[4-methyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 78243-17-1 HCAPLUS

CN 1H-Benzimidazole, 5-fluoro-2-[[5-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 78243-18-2 HCAPLUS


CN 1H-Benzimidazole, 5-methoxy-2-[[5-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 78243-19-3 HCAPLUS
CN Ethanone, 1-[2-[[(5-ethyl-2-pyridinyl)methyl]sulfinyl]-6-methyl-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 78243-20-6 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(2-pyridinylmethyl)sulfinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 78243-21-7 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[[(5-ethyl-2-pyridinyl)methyl]sulfinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 78243-22-8 HCAPLUS
CN 1H-Benzimidazole, 4-methyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)



L11 ANSWER 64 OF 69 HCAPLUS COPYRIGHT 2002 ACS

Full Text Citing References

ACCESSION NUMBER: 1980:198396 HCAPLUS
DOCUMENT NUMBER: 92:198396
TITLE: Substituted pyridylsulfinylbenzimidazoles having gastric acid secretion properties
INVENTOR(S): Junggren, Ulf Krister; Sjostrand, Sven Erik
PATENT ASSIGNEE(S): Aktiebolag Hassle, Swed.
SOURCE: Eur. Pat. Appl., 29 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent


LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>EP 5129</u>	A1	19791031	<u>EP 1979-850022</u>	19790403
<u>EP 5129</u>	B1	19810429		
R: BE, CH, DE, FR, GB, IT, LU, NL, SE				
<u>SE 7804231</u>	A	19791015	<u>SE 1978-4231</u>	19780414
<u>ZA 7901586</u>	A	19800430	<u>ZA 1979-1586</u>	19790403
<u>US 4255431</u>	A	19810310	<u>US 1979-27277</u>	19790405
<u>NO 7901227</u>	A	19791016	<u>NO 1979-1227</u>	19790410
<u>NO 152216</u>	B	19850513		
<u>NO 152216</u>	C	19850821		
<u>DK 7901511</u>	A	19791015	<u>DK 1979-1511</u>	19790411
<u>DK 150510</u>	B	19870316		
<u>DK 150510</u>	C	19871207		
<u>AU 7946027</u>	A1	19791018	<u>AU 1979-46027</u>	19790411
<u>AU 529654</u>	B2	19830616		
<u>FI 7901219</u>	A	19791015	<u>FI 1979-1219</u>	19790412
<u>FI 65067</u>	B	19831130		
<u>FI 65067</u>	C	19840312		
<u>DD 142882</u>	C	19800716	<u>DD 1979-212192</u>	19790412
<u>AT 7902732</u>	A	19830915	<u>AT 1979-2732</u>	19790412
<u>AT 374471</u>	B	19840425		
<u>HU 21380</u>	O	19811128	<u>HU 1979-HE782</u>	19790413
<u>HU 179022</u>	B	19820828		
<u>SU 895292</u>	A3	19811230	<u>SU 1979-2751500</u>	19790413
<u>CS 261851</u>	B2	19890210	<u>CS 1979-2549</u>	19790413
<u>CS 261873</u>	B2	19890210	<u>CS 1984-5768</u>	19790413
<u>CS 261874</u>	B2	19890210	<u>CS 1984-5769</u>	19790413
<u>JP 54141783</u>	A2	19791105	<u>JP 1979-44910</u>	19790414
<u>JP 60034956</u>	B4	19850812		
<u>SU 873879</u>	A3	19811015	<u>SU 1980-2867805</u>	19800118
<u>SU 873880</u>	A3	19811015	<u>SU 1980-2870599</u>	19800118
<u>SU 878196</u>	A3	19811030	<u>SU 1980-2870598</u>	19800118
<u>US 4337257</u>	A	19820629	<u>US 1980-150965</u>	19800519
<u>DK 8204209</u>	A	19820922	<u>DK 1982-4209</u>	19820922
<u>DK 151802</u>	B	19880104		
<u>DK 151802</u>	C	19880613		
<u>AT 8301006</u>	A	19830915	<u>AT 1983-1006</u>	19830322
<u>AT 374472</u>	B	19840425		
<u>AT 8301007</u>	A	19830915	<u>AT 1983-1007</u>	19830322
<u>AT 374473</u>	B	19840425		
<u>AT 8301005</u>	A	19831215	<u>AT 1983-1005</u>	19830322
<u>AT 375365</u>	B	19840725		
<u>US 4508905</u>	A	19850402	<u>US 1983-482513</u>	19830406
<u>JP 58192880</u>	A2	19831110	<u>JP 1983-69319</u>	19830421
<u>JP 63053191</u>	B4	19881021		
<u>FI 8302220</u>	A	19830617	<u>FI 1983-2220</u>	19830617
<u>FI 70214</u>	B	19860228		
<u>FI 70214</u>	C	19860912		
<u>AT 8302904</u>	A	19890815	<u>AT 1983-2904</u>	19830811
<u>AT 389995</u>	B	19900226		
<u>ES 527173</u>	A3	19850416	<u>ES 1983-527173</u>	19831111
<u>ES 527171</u>	A3	19850501	<u>ES 1983-527171</u>	19831111
<u>NO 8400112</u>	A	19791016	<u>NO 1984-112</u>	19840112
<u>NO 152785</u>	B	19850812		
<u>NO 152785</u>	C	19851120		
<u>CS 261872</u>	B2	19890210	<u>CS 1984-5767</u>	19840213
<u>AT 8901411</u>	A	19990715	<u>AT 1989-1411</u>	19890608
<u>AT 406119</u>	B	20000225		

PRIORITY APPLN. INFO.:

SE 1978-4231	19780414
US 1979-27277	19790405
DK 1979-1511	19790411
AT 1979-2732	19790412
FI 1979-1219	19790412
US 1980-150965	19800519
US 1982-369404	19820419
AT 1983-2904	19830811

GI




AB The sulfoxides I (R, R1 = H, alkyl, halogen, CO2Me, CO2Et, alkoxy, acyl; R2 = H, Me, Et; R3-R5 = H, Me, OMe, OEt, OCH2CH2OMe, OCH2CH2OEt) were prepd. by **oxidizing** the corresponding sulfides. Thus, 22.3 g I (R = 6-Me, R1 = 5-Ac, R2 = R3 = H, R4 = R5 = Me; II) was obtained by **oxidizing** 28.9 g of the sulfide with 3-ClC6H4CO2OH. II at 2 µmol/kg orally caused 90% gastric secretion inhibition in dogs.

IT 73590-65-5 73590-66-6 73590-67-7
73590-68-8 73590-69-9 73590-70-2
73590-71-3 73590-72-4 73590-73-5
73590-74-6 73590-75-7 73590-76-8
73590-77-9 73590-78-0 73590-79-1
73590-80-4 73590-81-5 73590-82-6
73590-83-7 73590-84-8 73590-85-9
73590-86-0 73590-87-1 73590-88-2
73590-89-3 73590-90-6 73598-38-6
73598-39-7

RL: RCT (Reactant)
 (oxidn. of)


RN 73590-65-5 HCAPLUS

CN Ethanone, 1-[2-[[[(4,5-dimethyl-2-pyridinyl)methyl]thio]-6-methyl-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 73590-66-6 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[[[(4,5-dimethyl-2-pyridinyl)methyl]thio]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 73590-67-7 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[[[(4,5-dimethyl-2-pyridinyl)methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)




RN 73590-68-8 HCAPLUS

CN Ethanone, 1-[2-[[3,4-dimethyl-2-pyridinyl)methyl]thio]-6-methyl-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 73590-69-9 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[[3,4-dimethyl-2-pyridinyl)methyl]thio]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 73590-70-2 HCAPLUS

CN 1H-Benzimidazole, 2-[[3,5-dimethyl-2-pyridinyl)methyl]thio]-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 73590-71-3 HCAPLUS

CN Ethanone, 1-[2-[[3,5-dimethyl-2-pyridinyl)methyl]thio]-6-methyl-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 73590-72-4 HCAPLUS

CN Ethanone, 1-[6-methyl-2-[[3,4,5-trimethyl-2-pyridinyl)methyl]thio]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 73590-73-5 HCAPLUS

CN Ethanone, 1-[2-[[4-methoxy-2-pyridinyl)methyl]thio]-6-methyl-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 73590-74-6 HCAPLUS

CN 1H-Benzimidazole, 2-[[4-methoxy-2-pyridinyl)methyl]thio]-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 73590-75-7 HCAPLUS

CN Ethanone, 1-[2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-6-methyl-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 73590-76-8 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[[3,5-dimethyl-2-pyridinyl)methyl]thio]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 73590-77-9 HCAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 6-methyl-2-[[3,4,5-trimethyl-2-pyridinyl)methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)




RN 73590-78-0 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[[4-methoxy-2-methyl-3-methyl-2-pyridinyl)methyl]thio]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 73590-79-1 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[[4-ethoxy-2-pyridinyl)methyl]thio]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 73590-80-4 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[[4-methoxy-3-methyl-2-pyridinyl)methyl]thio]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 73590-81-5 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[[4-methoxy-5-methyl-2-pyridinyl)methyl]thio]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 73590-82-6 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)




RN 73590-83-7 HCAPLUS
 CN Ethanone, 1-[2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 73590-84-8 HCAPLUS
 CN 1H-Benzimidazole, 5-methoxy-2-[[4-methoxy-5-methyl-2-pyridinyl)methyl]thio]- (9CI) (CA INDEX NAME)




RN 73590-85-9 HCAPLUS
 CN 1H-Benzimidazole, 5-methoxy-2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]- (9CI) (CA INDEX NAME)



RN 73590-86-0 HCAPLUS
 CN 1H-Benzimidazole, 2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-5-methyl- (9CI) (CA INDEX NAME)




RN 73590-87-1 HCAPLUS
 CN 1H-Benzimidazole, 2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]- (9CI) (CA INDEX NAME)




RN 73590-88-2 HCAPLUS

CN 1H-Benzimidazole, 5-chloro-2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]- (9CI) (CA INDEX NAME)




RN 73590-89-3 HCAPLUS

CN 1H-Benzimidazole, 2-[[[4-(2-methoxyethoxy)-2-pyridinyl)methyl]thio]-5-methyl- (9CI) (CA INDEX NAME)




RN 73590-90-6 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-, ethyl ester (9CI) (CA INDEX NAME)




RN 73598-38-6 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 73598-39-7 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[[[3,5-dimethyl-2-pyridinyl)methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)




IT 73590-36-0P 73590-37-1P 73590-38-2P
73590-39-3P 73590-40-6P 73590-41-7P
73590-42-8P 73590-43-9P 73590-44-0P
73590-45-1P 73590-46-2P 73590-47-3P
73590-48-4P 73590-49-5P 73590-50-8P
73590-51-9P 73590-52-0P 73590-53-1P
73590-54-2P 73590-55-3P 73590-56-4P
73590-57-5P 73590-58-6P 73590-59-7P
73590-60-0P 73590-61-1P 73590-62-2P
73590-63-3P

RL: SPN (Synthetic preparation); **PREP (Preparation)**
 (prepn. and gastric secretion-inhibiting activity of)


RN 73590-36-0 HCAPLUS

CN Ethanone, 1-[2-[[[(4,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-6-methyl-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 73590-37-1 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[[[(4,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 73590-38-2 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[[[(4,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 73590-39-3 HCAPLUS


CN Ethanone, 1-[2-[[[(3,4-dimethyl-2-pyridinyl)methyl]sulfinyl]-6-methyl-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 73590-40-6 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[[(3,4-dimethyl-2-pyridinyl)methyl]sulfinyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 73590-41-7 HCAPLUS
CN 1H-Benzimidazole, 2-[[(3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 73590-42-8 HCAPLUS
CN Ethanone, 1-[2-[[(3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-6-methyl-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)



RN 73590-43-9 HCAPLUS
CN Ethanone, 1-[6-methyl-2-[[(3,4,5-trimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 73590-44-0 HCAPLUS
CN Ethanone, 1-[2-[[(4-methoxy-2-pyridinyl)methyl]sulfinyl]-6-methyl-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 73590-45-1 HCAPLUS

CN 1H-Benzimidazole, 2-[[(4-methoxy-2-pyridinyl)methyl]sulfinyl]-4,6-dimethyl- (9CI) (CA INDEX NAME)




RN 73590-46-2 HCAPLUS

CN Ethanone, 1-[2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-6-methyl-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 73590-47-3 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[[(3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 73590-48-4 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 6-methyl-2-[[(3,4,5-trimethyl-2-pyridinyl)methyl]sulfinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 73590-49-5 HCAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[[(4-methoxy-2-pyridinyl)methyl]sulfinyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 73590-50-8 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[[4-ethoxy-2-pyridinyl)methyl]sulfinyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 73590-51-9 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[[4-methoxy-3-methyl-2-pyridinyl)methyl]sulfinyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 73590-52-0 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 73590-53-1 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[[4-methoxy-5-methyl-2-pyridinyl)methyl]sulfinyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 73590-54-2 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[[3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 73590-55-3 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 73590-56-4 HCAPLUS

CN Ethanone, 1-[2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 73590-57-5 HCAPLUS

CN 1H-Benzimidazole, 5-methoxy-2-[[[4-methoxy-5-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 73590-58-6 HCAPLUS

CN 1H-Benzimidazole, 5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 73590-59-7 HCAPLUS


CN 1H-Benzimidazole, 2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 73590-60-0 HCAPLUS
CN 1H-Benzimidazole, 2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 73590-61-1 HCAPLUS
CN 1H-Benzimidazole, 5-chloro-2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 73590-62-2 HCAPLUS
CN 1H-Benzimidazole, 2-[[4-(2-methoxyethoxy)-2-pyridinyl)methyl]sulfinyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 73590-63-3 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-, ethyl ester (9CI) (CA INDEX NAME)



L11 ANSWER 65 OF 69 HCAPLUS COPYRIGHT 2002 ACS


Full Text Citing References

ACCESSION NUMBER: 1979:593309 HCAPLUS
DOCUMENT NUMBER: 91:193309
TITLE: Benzimidazole derivatives
INVENTOR(S): Berntsson, Peder Bernhard; Carlsson, Stig Ake Ingemar; Garberg, Lars Erik; Junggren, Ulf Krister; Sjostrand, Sven Erik; Von Wittken Sundell, Gunhild Wika

PATENT ASSIGNEE(S): Aktiebolag Hassle, Swed.
 SOURCE: Fr. Demande, 21 pp. Division of Fr. Demande 2,331,340.
 CODEN: FRXXBL
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 8
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>FR 2392021</u>	<u>A1</u>	<u>19781222</u>	<u>FR 1976-16732</u>	<u>19760603</u>
<u>FR 2392021</u>	<u>B1</u>	<u>19790817</u>		
<u>FI 63756</u>	<u>B</u>	<u>19830429</u>	<u>FI 1975-2327</u>	<u>19750815</u>
<u>FI 63756</u>	<u>C</u>	<u>19830810</u>		
<u>FI 7502327</u>	<u>A</u>	<u>19770216</u>		
<u>CS 196289</u>	<u>P</u>	<u>19800331</u>	<u>CS 1975-7458</u>	<u>19751105</u>
<u>CH 623582</u>	<u>A</u>	<u>19810615</u>	<u>CH 1979-9760</u>	<u>19791031</u>
PRIORITY APPLN. INFO.:			<u>CH 1975-14814</u>	<u>19751114</u>
			<u>FR 1976-16732</u>	<u>19760603</u>

GI




AB 2-[(Heteroarylalkyl)thio]benzimidazoles I [R = alkyl, CONH₂, alkyl- or dialkylcarbamoyl, R₄COCH₂ (R₄ = alkyl), alkoxy-carbonylmethyl, alkylsulfonyl; R₁ and R₂ (same or different) = H, alkyl, halo, cyano, CO₂H, carboxyalkyl, carbalkoxy, carbalkoxyalkyl, carbamoyl, carbamoylalkyl, OH, alkoxy, hydroxyalkyl, CF₃, acyl; Z = linear or branched alkylene; R₃ = (un)substituted quinolyl of pyridyl] were prepd. from the resp. II (R₅ = SH, reactive acyloxy) and the resp. R₆ZR₃ (R₆ = reactive acyloxy, SH) and also by the reaction of o-phenylenediamines with the resp. R₃ZSCO₂H. I were converted to the resp. sulfoxides which inhibited gastric secretion. A mixt. of 2-mercaptobenzimidazole, 2-(chloromethyl)pyridine hydrochloride, aq. NaOH, and EtOH was refluxed 2 h to give I (R = R₁ = R₂ = H, Z = CH₂, R₃ = 2-pyridyl), which was **oxidized** by 3-ClC₆H₄C(O)OOH to yield the resp. sulfoxide.

IT 64588-75-6

RL: RCT (Reactant)

(gastric secretion inhibitor activity of)

RN 64588-75-6 HCAPLUS


CN 1H-Benzimidazole, 5-methyl-2-[[(4-methyl-2-pyridinyl)methyl]sulfinyl]-
 (9CI) (CA INDEX NAME)

IT 57237-97-5P 60524-78-9P 60524-79-0P
60524-80-3P 60524-83-6P 60524-87-0P
60524-97-2P 60524-98-3P 60524-99-4P
60525-00-0P

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. and gastric secretion inhibitor activity of)


RN 57237-97-5 HCAPLUS

CN 1H-Benzimidazole, 2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-78-9 HCAPLUS

CN 1H-Benzimidazole, 4,6-dimethyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-79-0 HCAPLUS

CN 1H-Benzimidazole, 5-ethyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-80-3 HCAPLUS

CN 1H-Benzimidazole, 6-chloro-4-methyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-83-6 HCAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 2-[(2-pyridinylmethyl)sulfinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 60524-87-0 HCAPLUS

CN 1H-Benzimidazole, 5-methyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-97-2 HCAPLUS

CN 1H-Benzimidazole, 2-[[(3-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-98-3 HCAPLUS

CN 1H-Benzimidazole, 2-[[(5-ethyl-2-pyridinyl)methyl]sulfinyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 60524-99-4 HCAPLUS

CN 1H-Benzimidazole, 2-[[(5-ethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 60525-00-0 HCAPLUS

CN 1H-Benzimidazole, 4-chloro-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




IT 60524-88-1P 60524-89-2P 60524-90-5P

60524-91-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and gastric secretion inhibitors activity of)


RN 60524-88-1 HCAPLUS

CN 1H-Benzimidazole, 5-chloro-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-89-2 HCAPLUS


CN 1H-Benzimidazole, 5-(1-methylethyl)-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-90-5 HCAPLUS
CN 1H-Benzimidazole, 5-propyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)



RN 60524-91-6 HCAPLUS
CN 1H-Benzimidazole, 5-methyl-2-[(5-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




IT 57258-32-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and N-acylation of)
RN 57258-32-9 HCAPLUS
CN 1H-Benzimidazole, 2-[(2-pyridinylmethyl)thio]-, monohydrochloride (9CI) (CA INDEX NAME)




HCl


IT 23593-22-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and S-oxidn. of)
RN 23593-22-8 HCAPLUS
CN 1H-Benzimidazole, 2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




IT 60524-81-4P 60524-82-5P 60524-88-1P
60525-02-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 60524-81-4 HCAPLUS
CN 1H-Benzimidazole, 5-methoxy-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-82-5 HCAPLUS
 CN Ethanone, 1-[2-[(2-pyridinylmethyl)sulfinyl]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)



RN 60524-88-1 HCAPLUS
 CN 1H-Benzimidazole, 5-chloro-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60525-02-2 HCAPLUS
 CN 1H-Benzimidazole, 5,6-dimethyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




IT 23593-24-0 64948-77-2 64948-78-3
64948-79-4 64948-80-7 64948-81-8
64948-83-0 64948-84-1 64948-85-2
64948-86-3 65140-13-8

RL: RCT (Reactant)
 (S-oxidn. of)


RN 23593-24-0 HCAPLUS
 CN 1H-Benzimidazole, 5-chloro-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 64948-77-2 HCAPLUS
 CN 1H-Benzimidazole, 4,6-dimethyl-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 64948-78-3 HCAPLUS
CN 1H-Benzimidazole, 5-ethyl-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 64948-79-4 HCAPLUS
CN 1H-Benzimidazole, 6-chloro-4-methyl-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 64948-80-7 HCAPLUS
CN 1H-Benzimidazole, 5-methoxy-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 64948-81-8 HCAPLUS
CN Ethanone, 1-[2-[(2-pyridinylmethyl)thio]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 64948-83-0 HCAPLUS
CN 1H-Benzimidazole, 5-methyl-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 64948-84-1 HCAPLUS
CN 1H-Benzimidazole, 5-(1-methylethyl)-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 64948-85-2 HCAPLUS
CN 1H-Benzimidazole, 5-propyl-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)



RN 64948-86-3 HCAPLUS
CN 1H-Benzimidazole, 5-methyl-2-[(5-methyl-2-pyridinyl)methyl]thio]- (9CI) (CA INDEX NAME)



RN 65140-13-8 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(2-pyridinylmethyl)thio]-, ethyl ester (9CI) (CA INDEX NAME)




L11 ANSWER 66 OF 69 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1979:557736 HCAPLUS
DOCUMENT NUMBER: 91:157736
TITLE: 2-(2-Heterocyclic-methylsulfinyl)benzimidazole compounds
INVENTOR(S): Berntsson, Peder B.; Carlsson, Stig A. I.; Garberg, Lars E.; Junggren, Ulf K.; Sjostrand, Sven E.; Von Wittken Sundeil, Gunhild W.
PATENT ASSIGNEE(S): Aktiebolag Hassle, Swed.
SOURCE: Can., 24 pp.
CODEN: CAXXA4
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 1055033	A1	19790522	CA 1975-239643	19751114
SE 416649	B	19810126	SE 1974-6513	19740516
SE 416649	C	19810507		
CH 623814	A	19810630	CH 1975-14814	19751114
PRIORITY APPLN. INFO.:			SE 1974-6513	19740516
			CA 1975-239643	19751114

GI




AB Benzimidazolyl sulfoxides I [R = H, alkyl, carbalkoxy, CONH₂, alkylcarbamoyl, alkylsulfonyl; Z = C1-4 linear or branched alkylene; R₁ = 2-pyridyl, alkyl-2-pyridyl, halo-2-pyridyl; R₂ and R₃ (same or different) are H, alkyl, halo, carbalkoxy, alkoxy, acyl], which inhibited gastric acid secretion, were prepd. by six different methods. The reaction of 2-(2-pyridylmethylthio)benzimidazole (II) with 3-ClC₆H₄C(O)OOH in CHCl₃ gave I (R = R₂ = R₃ = H, Z = CH₂, R₁ = 2-pyridyl). (2-□ Pyridylmethylthio)formic acid was heated with o-phenylenediamine in 4N HCl to yield II.

IT 60524-78-9P 60524-79-0P 60524-80-3P
60524-83-6P 60524-87-0P 60524-88-1P
60524-89-2P 60524-90-5P 60524-91-6P
60524-97-2P 60524-98-3P 60524-99-4P
60525-00-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and use of, as gastric secretion inhibitor)


RN 60524-78-9 HCAPLUS

CN 1H-Benzimidazole, 4,6-dimethyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-79-0 HCAPLUS

CN 1H-Benzimidazole, 5-ethyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-80-3 HCAPLUS

CN 1H-Benzimidazole, 6-chloro-4-methyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI)
(CA INDEX NAME)




RN 60524-83-6 HCAPLUS


CN 1H-Benzimidazole-5-carboxylic acid, 2-[(2-pyridinylmethyl)sulfinyl]-,
ethyl ester (9CI) (CA INDEX NAME)




RN 60524-87-0 HCAPLUS
CN 1H-Benzimidazole, 5-methyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-88-1 HCAPLUS
CN 1H-Benzimidazole, 5-chloro-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-89-2 HCAPLUS
CN 1H-Benzimidazole, 5-(1-methylethyl)-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-90-5 HCAPLUS
CN 1H-Benzimidazole, 5-propyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-91-6 HCAPLUS
CN 1H-Benzimidazole, 5-methyl-2-[(5-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-97-2 HCAPLUS
CN 1H-Benzimidazole, 2-[(3-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-98-3 HCAPLUS
CN 1H-Benzimidazole, 2-[[5-methyl-2-pyridinyl)methyl]sulfinyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 60524-99-4 HCAPLUS
CN 1H-Benzimidazole, 2-[[5-ethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 60525-00-0 HCAPLUS
CN 1H-Benzimidazole, 4-chloro-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




IT 57258-32-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and N-acylation of)
RN 57258-32-9 HCAPLUS
CN 1H-Benzimidazole, 2-[(2-pyridinylmethyl)thio]-, monohydrochloride (9CI) (CA INDEX NAME)□



#. HCl

IT 23593-22-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and S-oxidn. of)
RN 23593-22-8 HCAPLUS
CN 1H-Benzimidazole, 2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)



IT 57237-97-5P 60524-81-4P 60524-82-5P


60524-88-1P 71404-30-3P

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of)


RN 57237-97-5 HCAPLUS

CN 1H-Benzimidazole, 2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-81-4 HCAPLUS

CN 1H-Benzimidazole, 5-methoxy-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-82-5 HCAPLUS

CN Ethanone, 1-[2-[(2-pyridinylmethyl)sulfinyl]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)□




RN 60524-88-1 HCAPLUS

CN 1H-Benzimidazole, 5-chloro-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)



RN 71404-30-3 HCAPLUS

CN 1H-Benzimidazole, 4,5-dimethyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)



IT 23593-24-0 64948-77-2 64948-78-3

64948-79-4 64948-80-7 64948-81-8

64948-83-0 64948-84-1 64948-85-2


64948-86-3 65140-13-8

RL: RCT (Reactant)

(S-oxidn. of)


RN 23593-24-0 HCAPLUS

CN 1H-Benzimidazole, 5-chloro-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 64948-77-2 HCAPLUS

CN 1H-Benzimidazole, 4,6-dimethyl-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 64948-78-3 HCAPLUS

CN 1H-Benzimidazole, 5-ethyl-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 64948-79-4 HCAPLUS

CN 1H-Benzimidazole, 6-chloro-4-methyl-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME) □




RN 64948-80-7 HCAPLUS

CN 1H-Benzimidazole, 5-methoxy-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 64948-81-8 HCAPLUS


CN Ethanone, 1-[2-[(2-pyridinylmethyl)thio]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 64948-83-0 HCAPLUS
CN 1H-Benzimidazole, 5-methyl-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 64948-84-1 HCAPLUS
CN 1H-Benzimidazole, 5-(1-methylethyl)-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)□




RN 64948-85-2 HCAPLUS
CN 1H-Benzimidazole, 5-propyl-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)



RN 64948-86-3 HCAPLUS
CN 1H-Benzimidazole, 5-methyl-2-[(5-methyl-2-pyridinyl)methyl]thio]- (9CI) (CA INDEX NAME)□



RN 65140-13-8 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(2-pyridinylmethyl)thio]-, ethyl ester (9CI) (CA INDEX NAME)



L11 ANSWER 67 OF 69 HCAPLUS COPYRIGHT 2002 ACS


Full Text	Citing References
-----------	-------------------

ACCESSION NUMBER:	1978:105333 HCAPLUS
DOCUMENT NUMBER:	88:105333
TITLE:	Benzimidazole derivatives and their effects on stomach acid secretion
PATENT ASSIGNEE(S):	Aktiebolag Hassle, Swed.

SOURCE: Neth. Appl., 28 pp.
 CODEN: NAXXAN
 DOCUMENT TYPE: Patent
 LANGUAGE: Dutch
 FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>NL 7513141</u>	A	19770512	<u>NL 1975-13141</u>	19751110
<u>US 4045563</u>	A	19770830	<u>US 1975-630916</u>	19751111
PRIORITY APPLN. INFO.:			<u>US 1975-630916</u>	19751111
			<u>SE 1974-6513</u>	19740516

GI



AB Pyridylalkylsulfenylbenzimidazoles I (R = H, 4-Me, 5-Et, 5-OMe, 5-OH, 5-Ac, 5-CO₂H, 5-CO₂Et, 5-Me, 5-Cl, 5-CHMe₂, 5-CMe₃, 5-Pr, 5-CN, 5-CF₃, 4-Cl; R₁ = H, Me, Cl; R₂ = H, Me, Ac, CO₂Me, CONH₂, CONHMe, CH₂Ac, CH₂CO₂Et, SO₂Me; R₃ = H, Me, Et, CHMe₂; R₄ = H, 5-Me, 3-Me, 5-Et) (27 compds.) were prepd. by m-ClC₆H₄CO₂OH oxidn. of pyridylalkylthiobenzimidazoles prepd. e.g. by treating mercaptobenzimidazoles with 2-(1-chloroalkyl)pyridines. I are gastric acid secretion inhibitors. Thus, I (R-R₄ = H) at 1 mg/kg gave 90% inhibition of pentagastrin-induced stomach acid secretion in dogs.


IT 65680-57-1

RL: RCT (Reactant)

(acetylation of)

RN 65680-57-1 HCAPLUS

CN 1H-Benzimidazole, 2-[(2-pyridinylmethyl)thio]-, hydrochloride (9CI) (CA INDEX NAME)



x HCl

IT 23593-24-0 23593-28-4 64948-77-2

64948-78-3 64948-79-4 64948-80-7

64948-81-8 64948-83-0 64948-84-1

64948-85-2 64948-86-3 64948-90-9


64948-91-0 64948-92-1 65140-13-8

RL: RCT (Reactant)


(oxidn. of)

RN 23593-24-0 HCAPLUS


CN 1H-Benzimidazole, 5-chloro-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 23593-28-4 HCAPLUS
CN 1H-Benzimidazole, 5-chloro-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 64948-77-2 HCAPLUS
CN 1H-Benzimidazole, 4,6-dimethyl-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 64948-78-3 HCAPLUS
CN 1H-Benzimidazole, 5-ethyl-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 64948-79-4 HCAPLUS
CN 1H-Benzimidazole, 6-chloro-4-methyl-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 64948-80-7 HCAPLUS
CN 1H-Benzimidazole, 5-methoxy-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 64948-81-8 HCAPLUS
CN Ethanone, 1-[2-[(2-pyridinylmethyl)thio]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 64948-83-0 HCAPLUS
CN 1H-Benzimidazole, 5-methyl-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 64948-84-1 HCAPLUS
CN 1H-Benzimidazole, 5-(1-methylethyl)-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 64948-85-2 HCAPLUS
CN 1H-Benzimidazole, 5-propyl-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 64948-86-3 HCAPLUS
CN 1H-Benzimidazole, 5-methyl-2-[(5-methyl-2-pyridinyl)methyl]thio]- (9CI) (CA INDEX NAME)




RN 64948-90-9 HCAPLUS
CN 1H-Benzimidazole, 2-[(3-methyl-2-pyridinyl)methyl]thio]- (9CI) (CA INDEX NAME)




RN 64948-91-0 HCAPLUS
CN 1H-Benzimidazole, 2-[(5-ethyl-2-pyridinyl)methyl]thio]-5-methyl- (9CI) (CA INDEX NAME)



RN 64948-92-1 HCAPLUS
CN 1H-Benzimidazole, 2-[[5-ethyl-2-pyridinyl)methyl]thio]- (9CI) (CA INDEX NAME)




RN 65140-13-8 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(2-pyridinylmethyl)thio]-, ethyl ester (9CI) (CA INDEX NAME)




IT 23593-22-8P 57258-10-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and oxidn. of)

RN 23593-22-8 HCAPLUS
CN 1H-Benzimidazole, 2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)



RN 57258-10-3 HCAPLUS
CN 1H-Benzimidazole, 4-methyl-2-[(2-pyridinylmethyl)thio]-, monohydrochloride (9CI) (CA INDEX NAME)




HCl


IT 57237-97-5P 60524-78-9P 60524-79-0P
60524-80-3P 60524-83-6P 60524-87-0P
60524-88-1P 60524-89-2P 60524-90-5P
60524-91-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and stomach acid secretion-inhibiting activity of)


RN 57237-97-5 HCAPLUS
CN 1H-Benzimidazole, 2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-78-9 HCAPLUS
CN 1H-Benzimidazole, 4,6-dimethyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-79-0 HCAPLUS
CN 1H-Benzimidazole, 5-ethyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-80-3 HCAPLUS
CN 1H-Benzimidazole, 6-chloro-4-methyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-83-6 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(2-pyridinylmethyl)sulfinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 60524-87-0 HCAPLUS
CN 1H-Benzimidazole, 5-methyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-88-1 HCAPLUS
CN 1H-Benzimidazole, 5-chloro-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-89-2 HCAPLUS
CN 1H-Benzimidazole, 5-(1-methylethyl)-2-[(2-pyridinylmethyl)sulfinyl]- (9CI)
(CA INDEX NAME)



RN 60524-90-5 HCAPLUS
CN 1H-Benzimidazole, 5-propyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA
INDEX NAME)




RN 60524-91-6 HCAPLUS
CN 1H-Benzimidazole, 5-methyl-2-[(5-methyl-2-pyridinyl)methylsulfinyl]-
(9CI) (CA INDEX NAME)




IT 60524-81-4P 60524-82-5P 60524-88-1P
60524-97-2P 60524-98-3P 60524-99-4P
60525-02-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 60524-81-4 HCAPLUS
CN 1H-Benzimidazole, 5-methoxy-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA
INDEX NAME)




RN 60524-82-5 HCAPLUS
CN Ethanone, 1-[2-[(2-pyridinylmethyl)sulfinyl]-1H-benzimidazol-5-yl]- (9CI)
(CA INDEX NAME)




RN 60524-88-1 HCAPLUS
CN 1H-Benzimidazole, 5-chloro-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA

INDEX NAME)




RN 60524-97-2 HCAPLUS

CN 1H-Benzimidazole, 2-[[3-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-98-3 HCAPLUS

CN 1H-Benzimidazole, 2-[[5-ethyl-2-pyridinyl)methyl]sulfinyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 60524-99-4 HCAPLUS

CN 1H-Benzimidazole, 2-[[5-ethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 60525-02-2 HCAPLUS

CN 1H-Benzimidazole, 5,6-dimethyl-2-[(2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




IT 64588-75-6

RL: RCT (Reactant)

(stomach acid secretion-inhibiting activity of)

RN 64588-75-6 HCAPLUS

CN 1H-Benzimidazole, 5-methyl-2-[[4-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




L11 ANSWER 68 OF 69 HCAPLUS COPYRIGHT 2002 ACS

Full Text Citing References

ACCESSION NUMBER: 1978:22909 HCAPLUS
 DOCUMENT NUMBER: 88:22909
 TITLE: Benzimidazole derivatives and their salts
 INVENTOR(S): Berntsson, Peder Bernhard; Carlsson, Stig Ake Ingemar; Garberg, Lars Erik; Junggren, Ulf Krister; Sjostrand, Sven Erik; Von Wittken Sundell, Gunhild Wika
 PATENT ASSIGNEE(S): Aktiebolag Hassle, Swed.
 SOURCE: Austrian, 10 pp.
 CODEN: AUXXAK
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 8
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>AT 337697</u>	B	19770711	<u>AT 1975-8380</u>	19751104
<u>AT 7508380</u>	A	19761115		
<u>US 4045563</u>	A	19770830	<u>US 1975-630916</u>	19751111
<u>AT 351524</u>	B	19790725	<u>AT 1976-7522</u>	19761011
<u>AT 7607522</u>	A	19790115		
PRIORITY APPLN. INFO.:			US 1975-630916	19751111
			SE 1974-6513	19740516
			<u>AT 1975-8380</u>	19751104

GI




AB Pyridylalkylthiobenzimidazoles were **oxidized** with m-ClC6H4CO3H to give ~30 I (R = H, 4-, 5-Me, 5-OMe, 5-Ac, 5-CO2Et, 5-CMe3, 4-, 6-Cl, 5-CF3, 5-CN, etc.; R1 = H, Me, Ac, CO2Me, CONHMe, SO2Me, etc.; Z = CH2, CHMe, CHet, CHCHMe2; R2 = H, 3-, 4-, 5-Me, 5-Et, 4-Cl). I in doses of 1-10 mg/kg showed 8-96% inhibition of secretion of stomach acid.

IT 57258-32-9

RL: **RCT (Reactant)**
 (acylation of)

RN 57258-32-9 HCAPLUS

CN 1H-Benzimidazole, 2-[(2-pyridinylmethyl)thio]-, monohydrochloride (9CI)
 (CA INDEX NAME)




HCl

IT 23593-24-0 23593-28-4 64948-77-2
64948-78-3 64948-79-4 64948-80-7
64948-81-8 64948-83-0 64948-84-1
64948-85-2 64948-86-3 64948-90-9
64948-91-0 64948-92-1 64948-93-2
65140-13-8

RL: RCT (Reactant)
 (oxidn. of)


RN 23593-24-0 HCAPLUS

CN 1H-Benzimidazole, 5-chloro-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 23593-28-4 HCAPLUS

CN 1H-Benzimidazole, 5,6-dimethyl-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 64948-77-2 HCAPLUS

CN 1H-Benzimidazole, 4,6-dimethyl-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 64948-78-3 HCAPLUS

CN 1H-Benzimidazole, 5-ethyl-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 64948-79-4 HCAPLUS

CN 1H-Benzimidazole, 6-chloro-4-methyl-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 64948-80-7 HCAPLUS

CN 1H-Benzimidazole, 5-methoxy-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 64948-81-8 HCAPLUS

CN Ethanone, 1-[2-[(2-pyridinylmethyl)thio]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 64948-83-0 HCAPLUS

CN 1H-Benzimidazole, 5-methyl-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 64948-84-1 HCAPLUS

CN 1H-Benzimidazole, 5-(1-methylethyl)-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 64948-85-2 HCAPLUS

CN 1H-Benzimidazole, 5-propyl-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 64948-86-3 HCAPLUS


CN 1H-Benzimidazole, 5-methyl-2-[(5-methyl-2-pyridinyl)methyl]thio]- (9CI) (CA INDEX NAME)




RN 64948-90-9 HCAPLUS
CN 1H-Benzimidazole, 2-[(3-methyl-2-pyridinyl)methyl]thio]- (9CI) (CA INDEX NAME)




RN 64948-91-0 HCAPLUS
CN 1H-Benzimidazole, 2-[(5-ethyl-2-pyridinyl)methyl]thio]-5-methyl- (9CI) (CA INDEX NAME)




RN 64948-92-1 HCAPLUS
CN 1H-Benzimidazole, 2-[(5-ethyl-2-pyridinyl)methyl]thio]- (9CI) (CA INDEX NAME)



RN 64948-93-2 HCAPLUS
CN 1H-Benzimidazole, 4-chloro-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 65140-13-8 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(2-pyridinylmethyl)thio]-, ethyl ester (9CI) (CA INDEX NAME)




IT 23593-22-8P 60525-11-3P
RL: **RCT (Reactant)**; SPN (Synthetic preparation); PREP
(Preparation)
(prepn. and oxidn. of)

RN 23593-22-8 HCAPLUS
CN 1H-Benzimidazole, 2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




RN 60525-11-3 HCAPLUS
CN 1H-Benzimidazole, 4-methyl-2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)




IT 60524-78-9P 60524-79-0P 60524-80-3P
60524-83-6P 60524-87-0P 60524-88-1P
60524-89-2P 60524-90-5P 60524-91-6P
60524-97-2P 60524-98-3P 60524-99-4P
60525-00-0P

RL: SPN (Synthetic preparation); **PREP (Preparation)**
(prepn. and stomach acid secretion inhibiting activity of)


RN 60524-78-9 HCAPLUS
CN 1H-Benzimidazole, 4,6-dimethyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-79-0 HCAPLUS
CN 1H-Benzimidazole, 5-ethyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-80-3 HCAPLUS
CN 1H-Benzimidazole, 6-chloro-4-methyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-83-6 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(2-pyridinylmethyl)sulfinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 60524-87-0 HCAPLUS
CN 1H-Benzimidazole, 5-methyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-88-1 HCAPLUS
CN 1H-Benzimidazole, 5-chloro-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-89-2 HCAPLUS
CN 1H-Benzimidazole, 5-(1-methylethyl)-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-90-5 HCAPLUS
CN 1H-Benzimidazole, 5-propyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)



RN 60524-91-6 HCAPLUS
CN 1H-Benzimidazole, 5-methyl-2-[(5-methyl-2-pyridinyl)methylsulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-97-2 HCAPLUS
CN 1H-Benzimidazole, 2-[(3-methyl-2-pyridinyl)methylsulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-98-3 HCAPLUS

CN 1H-Benzimidazole, 2-[[5-methyl-2-pyridinyl)methyl]sulfinyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 60524-99-4 HCAPLUS

CN 1H-Benzimidazole, 2-[[5-ethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 60525-00-0 HCAPLUS

CN 1H-Benzimidazole, 4-chloro-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




IT 57237-97-5P 60524-81-4P 60524-82-5P

60524-88-1P 60525-02-2P

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)


RN 57237-97-5 HCAPLUS

CN 1H-Benzimidazole, 2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-81-4 HCAPLUS

CN 1H-Benzimidazole, 5-methoxy-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-82-5 HCAPLUS

CN Ethanone, 1-[2-[(2-pyridinylmethyl)sulfinyl]-1H-benzimidazol-5-yl]- (9CI)
(CA INDEX NAME)




RN 60524-88-1 HCAPLUS

CN 1H-Benzimidazole, 5-chloro-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)



RN 60525-02-2 HCAPLUS

CN 1H-Benzimidazole, 5,6-dimethyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




IT 64588-75-6

RL: RCT (Reactant)

(stomach acid secretion inhibiting activity of)

RN 64588-75-6 HCAPLUS

CN 1H-Benzimidazole, 5-methyl-2-[[4-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



L11 ANSWER 69 OF 69 HCAPLUS COPYRIGHT 2002 ACS

Full Text Citing References

ACCESSION NUMBER: 1977:601543 HCAPLUS

DOCUMENT NUMBER: 87:201543

TITLE: Substituted 2-[pyridylalkylenesulfinyl]-benzimidazoles with gastric acid secretion inhibiting effects

INVENTOR(S): Berntsson, Peder Bernhard; Carlsson, Stig Ake Ingemar; Garberg, Lars Erik; Junggren, Ulf Krister; Sjostrand, Sven Erik; Von Wittken Sundell, Gunhild Wika

PATENT ASSIGNEE(S): Aktiebolag Hassle, Swed.

SOURCE: U.S., 13 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>US 4045563</u>	A	19770830	<u>US 1975-630916</u>	19751111
<u>SE 416649</u>	B	19810126	<u>SE 1974-6513</u>	19740516
SE 416649	C	19810507		
<u>DK 140840</u>	B	19791126	<u>DK 1975-3721</u>	19750818
DK 140840	C	19800505		
<u>AU 498140</u>	B2	19790215	<u>AU 1975-86258</u>	19751103
<u>AT 337697</u>	B	19770711	<u>AT 1975-8380</u>	19751104
AT 7508380	A	19761115		
<u>NL 7513141</u>	A	19770512	<u>NL 1975-13141</u>	19751110
PRIORITY APPLN. INFO.:			SE 1974-6513	19740516
			US 1975-630916	19751111

GI




AB Benzimidazoles I (R = H, Me, Ac, CO₂Me, CONH₂, CONHMe, CH₂Ac, CH₂CO₂Et, SO₂Me; R₁ = H, Me, Et, CHMe₂; R₂ = H, 4-Cl, 5-Me, 4-Me, 3-Me, 5-Et; R₃ = H, 4-Me, 5-Et, 5-OMe, 5-OH, 5-Ac, 5-CO₂H, 5-CO₂Et, 5-Me, 5-CMe₃, 5-Br, 5-CHMe₂, 5-Cl, 5-CF₃, 5-CMe₃, 5-Pr, 5-CN; R₄ = H, Me, Cl) (38 compds.) were prepd. e.g. by **oxidizing** pyridylmethylthiobenzimidazoles. I are gastric acid secretion inhibitors. Thus, I (R-R₂ = H, R₃ = 4-Me, R₄ = ME) at 5 mg/kg orally in dogs caused 94% inhibition on pentagastrin-induced gastric acid secretion.

IT 23593-22-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and **oxidn.** of)

RN 23593-22-8 HCAPLUS

CN 1H-Benzimidazole, 2-[(2-pyridinylmethyl)thio]- (9CI) (CA INDEX NAME)



IT 60524-79-0P 60524-80-3P 60524-83-6P

60524-87-0P 60524-88-1P 60524-89-2P


60524-90-5P 60524-91-6P 60524-97-2P

60524-98-3P 60524-99-4P 60525-00-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and stomach acid secretion inhibiting activity of)


RN 60524-79-0 HCAPLUS

CN 1H-Benzimidazole, 5-ethyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-80-3 HCAPLUS


CN 1H-Benzimidazole, 6-chloro-4-methyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-83-6 HCAPLUS
CN 1H-Benzimidazole-5-carboxylic acid, 2-[(2-pyridinylmethyl)sulfinyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 60524-87-0 HCAPLUS
CN 1H-Benzimidazole, 5-methyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-88-1 HCAPLUS
CN 1H-Benzimidazole, 5-chloro-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-89-2 HCAPLUS
CN 1H-Benzimidazole, 5-(1-methylethyl)-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-90-5 HCAPLUS
CN 1H-Benzimidazole, 5-propyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-91-6 HCAPLUS
CN 1H-Benzimidazole, 5-methyl-2-[(5-methyl-2-pyridinyl)methylsulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-97-2 HCAPLUS
CN 1H-Benzimidazole, 2-[[3-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-98-3 HCAPLUS
CN 1H-Benzimidazole, 2-[[5-ethyl-2-pyridinyl)methyl]sulfinyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 60524-99-4 HCAPLUS
CN 1H-Benzimidazole, 2-[[5-ethyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 60525-00-0 HCAPLUS
CN 1H-Benzimidazole, 4-chloro-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)



IT 60524-78-9P

RL: SPN (Synthetic preparation); **PREP (Preparation)**
(prepn. and stomach secretion inhibiting effects on)

RN 60524-78-9 HCAPLUS
CN 1H-Benzimidazole, 4,6-dimethyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




IT 57237-97-5P 60524-81-4P 60524-82-5P
60524-88-1P 60525-02-2P 64588-66-5P
64588-67-6P 64588-68-7P 64588-69-8P
64588-70-1P 64588-71-2P

RL: SPN (Synthetic preparation); **PREP (Preparation)**
 (prepn. of)


RN 57237-97-5 HCAPLUS

CN 1H-Benzimidazole, 2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-81-4 HCAPLUS

CN 1H-Benzimidazole, 5-methoxy-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60524-82-5 HCAPLUS

CN Ethanone, 1-[2-[(2-pyridinylmethyl)sulfinyl]-1H-benzimidazol-5-yl]- (9CI) (CA INDEX NAME)




RN 60524-88-1 HCAPLUS

CN 1H-Benzimidazole, 5-chloro-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 60525-02-2 HCAPLUS


CN 1H-Benzimidazole, 5,6-dimethyl-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 64588-66-5 HCAPLUS
CN 1H-Benzimidazole, 2-[[(4-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 64588-67-6 HCAPLUS
CN 1H-Benzimidazole, 5-(1,1-dimethylethyl)-2-[[(5-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)




RN 64588-68-7 HCAPLUS
CN 1H-Benzimidazole, 5-bromo-2-[(2-pyridinylmethyl)sulfinyl]- (9CI) (CA INDEX NAME)




RN 64588-69-8 HCAPLUS
CN 1H-Benzimidazole, 5-(1-methylethyl)-2-[[(5-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 64588-70-1 HCAPLUS
CN 1H-Benzimidazole, 5-chloro-2-[[(5-methyl-2-pyridinyl)methyl]sulfinyl]- (9CI) (CA INDEX NAME)



RN 64588-71-2 HCAPLUS
CN 1H-Benzimidazole, 2-[(2-pyridinylmethyl)sulfinyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)




IT **64588-75-6**

RL: **RCT (Reactant)**

(stomach acid secretion inhibition activity of)

RN **64588-75-6 HCAPLUS**

CN **1H-Benzimidazole, 5-methyl-2-[[(4-methyl-2-pyridinyl)methyl]sulfinyl]-**
(9CI) (CA INDEX NAME)



=> **file casreact**

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
317.81	601.10

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-42.75	-42.75

CA SUBSCRIBER PRICE

FILE 'CASREACT' ENTERED AT 17:21:27 ON 11 AUG 2002

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE CONTENT:1974 - 11 Aug 2002 VOL 137 ISS 6

Some records from 1974 to 1991 are derived from the ZIC/VINITI data file and provided by InfoChem.

This file contains CAS Registry Numbers for easy and accurate substance identification.

Functional group classes (FGC) were not generated for records that were added to the CASREACT file between 1/12/02 and 6/13/02. Use of functional group terms in online and current-awareness alert (SDI) searches during this period, may have yielded incomplete results. As of 6/13/02, the situation has been resolved. Also, note that regular functional groups (FGA) were not affected.

Customers running online and/or current-awareness alert searches in the CASREACT file between 1/12/02 and 6/13/02 are encouraged to re-run these strategies. Contact the CAS Help Desk at 1-800-848-6533 in North America or 1-614-447-3698, worldwide, or send an e-mail to help@cas.org, for further assistance or to receive a credit for any duplicate searches.

Crossover limits have been increased. See [HELP RNCROSSOVER](#) for details.

Structure search limits have been raised. See [HELP SLIMIT](#) for the new, higher limits.

=>

L12 STRUCTURE UPLOADED

=> d 112
L12 HAS NO ANSWERS
L12 STR

Ak 52H 53


H 50 Ak 51

20 Ak 0 18


21
Ak
S
19

RRT

Page 1-A




Page 1-B



Page 1-C

G3 24



Page 2-A


C
01

RRT
10 C M2

12 N

C
11 M1


Page 2-B




Page 2-C

PRD

G3 049



Page 3-A



Page 3-B



Page 4-A

VAR G2=50/51

VAR G3=52/53/18/19

REP G19=(1-2) 38-36 38-41

REP G20=(1-2) 10-13 10-25

VPA 24-1/2/3 S

VPA 49-27/28/29 S

NODE ATTRIBUTES:

HCOUNT	IS M1	AT	7
HCOUNT	IS M2	AT	10
HCOUNT	IS M1	AT	11
HCOUNT	IS M1	AT	33
HCOUNT	IS M2	AT	38
HCOUNT	IS M1	AT	39
NSPEC	IS R	AT	1
NSPEC	IS R	AT	2
NSPEC	IS R	AT	3
NSPEC	IS R	AT	4
NSPEC	IS R	AT	5
NSPEC	IS R	AT	6
NSPEC	IS R	AT	7
NSPEC	IS R	AT	8
NSPEC	IS R	AT	9
NSPEC	IS C	AT	10
NSPEC	IS R	AT	11
NSPEC	IS R	AT	12
NSPEC	IS R	AT	13
NSPEC	IS R	AT	14
NSPEC	IS R	AT	15
NSPEC	IS R	AT	16
NSPEC	IS C	AT	17
NSPEC	IS C	AT	18
NSPEC	IS C	AT	19
NSPEC	IS C	AT	20


```

NSPEC  IS C      AT  21
NSPEC  IS C      AT  22
NSPEC  IS C      AT  23
NSPEC  IS C      AT  24
NSPEC  IS C      AT  25
NSPEC  IS C      AT  26
NSPEC  IS R      AT  27
NSPEC  IS R      AT  28
NSPEC  IS R      AT  29
NSPEC  IS R      AT  30
NSPEC  IS R      AT  31
NSPEC  IS R      AT  32
NSPEC  IS R      AT  33
NSPEC  IS R      AT  34
NSPEC  IS R      AT  35
NSPEC  IS C      AT  36
NSPEC  IS C      AT  37
NSPEC  IS C      AT  38
NSPEC  IS R      AT  39
NSPEC  IS R      AT  40
NSPEC  IS R      AT  41
NSPEC  IS R      AT  42
NSPEC  IS R      AT  43
NSPEC  IS R      AT  44
NSPEC  IS C      AT  45
NSPEC  IS C      AT  46
NSPEC  IS C      AT  47
NSPEC  IS C      AT  48
NSPEC  IS C      AT  49
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS AT 10 18 19 20 21 25 36 37 38 50 51 52 53
DEFAULT ECLEVEL IS LIMITED

```

GRAPH ATTRIBUTES:
 RSPEC I
 NUMBER OF NODES IS 53

STEREO ATTRIBUTES: NONE

=> s 112

SAMPLE SEARCH INITIATED 17:31:02 FILE 'CASREACT'
 SCREENING COMPLETE - 0 REACTIONS TO VERIFY FROM 0 DOCUMENTS
 100.0% DONE 0 VERIFIED 0 HIT RXNS 0 DOCS
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED VERIFICATIONS: 0 TO 0
 PROJECTED ANSWERS: 0 TO 0

L13 0 SEA SSS SAM L12 (0 REACTIONS)

=> s 112 full

FULL SEARCH INITIATED 17:31:16 FILE 'CASREACT'
 SCREENING COMPLETE - 0 REACTIONS TO VERIFY FROM 0 DOCUMENTS
 100.0% DONE 0 VERIFIED 0 HIT RXNS 0 DOCS
 SEARCH TIME: 00.00.01

L14 0 SEA SSS FUL L12 (0 REACTIONS)

=> file caold

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
----------------------	------------	-------

FULL ESTIMATED COST	ENTRY 98.86	SESSION 699.96
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-42.75

FILE 'CAOLD' ENTERED AT 17:31:42 ON 11 AUG 2002
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
 FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d his

(FILE 'HOME' ENTERED AT 17:14:46 ON 11 AUG 2002)

FILE 'REGISTRY' ENTERED AT 17:14:55 ON 11 AUG 2002

L1 STRUCTURE UPLOADED
 L2 48 S L1
 L3 901 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 17:15:44 ON 11 AUG 2002

L4 212 S L3/PREP

FILE 'REGISTRY' ENTERED AT 17:15:55 ON 11 AUG 2002

L5 STRUCTURE UPLOADED
 L6 50 S L5
 L7 1638 S L5 FULL

FILE 'HCAPLUS' ENTERED AT 17:17:21 ON 11 AUG 2002

L8 176 S L7/RCT
 L9 122 S L8 AND L4
 L10 105 S L9 AND PD < MARCH 2001
 L11 69 S L10 AND OXID?

FILE 'CASREACT' ENTERED AT 17:21:27 ON 11 AUG 2002

L12 STRUCTURE UPLOADED
 L13 0 S L12
 L14 0 S L12 FULL

FILE 'CAOLD' ENTERED AT 17:31:42 ON 11 AUG 2002

=> s 13 and 17

0 L3
 0 L7
 L15 0 L3 AND L7

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.38	700.34

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-42.75

STN INTERNATIONAL LOGOFF AT 17:32:22 ON 11 AUG 2002